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ABSTRACT OF DISSERTATION 
 
 
CHIRAL 1,2−DIAMINO GUESTS IN CHAIN REPLACEMENT 
PEPTIDOMIMETICS: A NEW HELICAL MOTIF 
 
Peptides are short, sequence and length specific oligomers composed of 
small amino acid residues. Nature has refined these peptide sequences and their 
endogenous function through evolution. In addition, peptides have played an 
important role in medicine, which has lead to further research into developing 
peptides as lead pharmaceuticals (therapeutic peptides). Unfortunately, 
therapeutic peptides are inferior as drug candidates due to their low oral 
bioavailability; immunogenicity and potential to be attacked by peptidases. 
Fortunately, peptides can be modified by steric constraints, cyclization, and/or 
replacement of the peptide backbone itself creating a mimic (peptidomimetic) of 
the original peptide. Peptidomimetics are deliberately designed to have increased 
protease resistance, reduced immunogenicity and improved bioavailability when 
compared to the original endogenous peptide. One such peptide, Magainin is a      
O One such peptide, Magainin is a well-studied, α-helical peptide found in 
African clawed frogs. This peptide has antibiotic properties (against pathogenic 
bacteria), which partly arises from the hydrophilic portion of the peptide having 
basic amino acid side chains periodically disposed on one side of the α−helix. 
This property of magainin causes its attraction to negatively charged bacteria cell
membranes. Unfortunately, as in the case of other antibiotics, pathogenic 
bacteria have developed effective countermeasures against magainin. We 
designed a peptidomimetic based on magainin and implemented a plan to 
determine what type of molecules could be assembled for a magainin mimic. We 
successfully utilized molecular modeling (Monte Carlo conformational search), as 
well as results from previous experiments to elucidate what type of molecules, as 
well as how many molecules would be necessary to create a novel helical-like 
magainin peptidomimetic. It was discovered that C2 symmetric diamines would 
be best at generating the helical-like motif and the amino acid lysine to generate 
the basic side chain. The next step was the successful connection of two C2 
symmetric molecules via a urea linkage and then one more connection to a 
lysine (α−amino group) residue, creating a short sequence of oligoureas 
(trimers). Finally, attempts to connect the oligoureas trimers were attempted 
using a solid-phase synthesis approach to generate a functional magainin mimic. 
KEYWORDS: Peptidomimetics, Antibiotics, Magainin, Helices, Solid Phase  
Synthesis 
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Chapter 1 
Rational Peptidomimetic Design 
 
1.1 Overview of Dissertation 
This dissertation is divided into four chapters. In chapter one, “Rational 
Peptidomimic Design”, the use of peptidomimetics as therapeutic agents will be 
discussed, as well as the application of molecular modeling to develop the 
profile(s) of a peptidomimetic of interest. Based on a naturally occurring antibiotic 
peptide and using the results generated from molecular modeling, we developed 
a plan to create these compounds through solution and solid-phase synthesis.  
Chapter 2, entitled “A Brief Review on Cationic Peptide Antibiotics”, discusses 
the history and diversity of antibiotic peptides, as well as their different modes of 
action against pathogenic bacteria with special interest directed towards the 
helical antibiotic peptide, Magainin. Chapter 3, “Experimental Section”, will 
discuss the experimental program needed for the manufacture of target 
compounds, as well as eventual assembly via fragment condensation. The fourth 
and final chapter “Conclusions” summarizes the results obtained from this 
dissertation work.  
1.2 Introduction to Peptidomimetics  
Peptides play an important role in medicine, physiology and pharmacology. Many 
naturally occurring peptides function as hormones, growth factors1,2, antibiotics 
and are implicated in diseases, such as Alzheimers.3,4 Nature has refined 
naturally occurring peptide sequences and their endogenous function through 
evolution. This has led to significant interest in exploiting peptides as lead 
pharmaceutical compounds, mainly in the areas of antibiotics5, cancer2, immune 
system6 and cardiovascular diseases.7 Unfortunately, peptides themselves are 
inferior as drug candidates due to several factors including: their low oral 
bioavailability; immunogenicity and potential to be attacked by peptidases.5 
However, peptides can be modified by using steric constraints, cyclization, and/or 
replacement of the peptide backbone itself or possibly a small part of the 
backbone to stabilize the bioactive conformation and fine tune bioavailability.  
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Figure 1.1. Peptoids. Peptoids are        Figure 1.2. γ−Peptides. This structure is  
composed of N−substituited glycines.     a generalized representation of a class 
                                                                of compounds known as γ−peptides.                            
 
 
 
 
  
 
 
                        Figure 1.3. N,N’− linked oligoureas. This structure 
                        is a generalized representation of a N,N’−linked 
                        oligourea. 
 
These novel compounds that have new/maintained biological and/or chemical 
function are referred to as peptidomimetics.5  Peptidomimetics are deliberately 
designed to have increased protease resistance, reduced immunogenicity and 
improved bioavailability when compared with the natural peptides. In addition to 
this, a peptidomimetic may fold to create well-defined secondary structural 
elements such as helices, turns and small sheet-like structures allowing for 
biological or chemical activity. The term foldamer broadly encompasses these 
molecules and are not just limited to peptidomimetics.8 In general, a foldamer is 
any oligomeric molecule consisting of some regularly repeating motif that adopts 
a constrained conformation in solution (with a loss of chain entropy). Foldamers 
are divided into two major classes: biotic (natural and closely related  backbones) 
and abiotic (non-natural synthetic backbones) depending on their chemical 
composition.8  Among these, peptidomimetic foldamers and single-stranded 
abiotic foldamers are the best developed. Peptidomimetic foldamers, including 
peptoids9 (Figure 1.1), and γ−peptides10 (Figure 1.2),  N,N−linked oligoureas11 
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(Figure 1.3), are created from a design that involves systematic structural 
variations of parent chain molecules which are known to adopt predominant 
conformations. Single-stranded abiotic foldamers including oligo(m-phenylene 
ethynylene)13  (Figure 1.4) and aedamers12 (Figure 1.5) arise from a design that 
involves novel, abiotic backbones which fold into conformationally ordered states. 
Foldamers have applications such as temperature sensors14 and molecular 
recognition14 elements in non−biological and biological systems. 
In addition to this, molecular folding is influenced by solvent interactions and 
conformation, which arise from non-covalent interactions between non−adjacent 
monomer units. Therefore, the development of synthetic foldamers provides 
scientists with an excellent opportunity to explore various relationships between 
structures, molecular shapes, and functions.   
 
 
 
 
          
            Figure 1.4.  An oligo(m−phenylene ethynylene) foldamer. 
 
1.3 Design of Foldamers 
Although, the ideas for foldameric design come from concepts derived from 
biophysics and polymer science, it would be best to design a foldamer and 
predict/utilize its properties by studying previously known foldamers.  
                      Figure 1.5.  An aedamer. Another foldameric motif. 
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To understand a foldamer’s properties we must take into consideration the 
mechanism(s) of folding, as well as identifying the kinetic and thermodynamic  
 
 
 
 
                               An Amide                                   An Urea 
                Figure 1.6.  Amides and Ureas. Ureas are more stable  
                and more conformationally flexible than an amide due to  
                the donation of electrons from both nitrogens into the  
                C−O antibonding orbital. 
         
properties responsible for folding to occur.15 The path to creating successful and 
useful foldamers involves several factors, including: preparation of the parent 
monomers (that the foldamer is comprised of) in a stereochemically pure form; 
identification of novel backbones that have suitable folding propensities; carrying 
out tests on the newly created foldamer for interesting biological/chemical 
function(s) and probably one of the most important factors is the efficient 
production of the foldamer itself. Of course, repetition will occur until the desired 
outcome is obtained. The types of secondary structures most crucial for foldamer 
development are those that display “long-range order”, such as helices and 
sheets. One important aspect of this “long range order” is cooperativity, which will 
improve the integrity of the active sites in the folded states. Cooperativity 
suggests that the next unit of global conformation forms faster due to the 
presence of the preceding unit. This is important, because a cooperative 
structure will tend to have the most important groups in the correct location for 
most of the time, since the entire structure is more stable than the sum of its 
parts. Earlier it was mentioned that before one can think about the molecular 
tasks a foldamer might perform, it must be designed with a predictable outcome 
(shape), in mind. We can apply this principle to our own molecules, using a C2 
symmetric molecule as a guide. A C2 symmetric molecule, in principle, should be 
able to translate its local symmetry into a global ‘helical’ shape. (Helices, in 
general, have C2 as the only symmetry point group operation). However, a 
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few issues must be considered to make the design remotely feasible. When 
designing a peptidomimetic, one has to consider the multiple interactions and 
behaviors of the constituent monomer units.16 Here, the more important internal 
peptidomimic interactions will be broken down to describe the different aspects 
that have to be considered. The first and probably most important aspect of a 
peptidomimetic and its behavior will arise from the backbone. In our case, the 
peptidomimetic’s backbone will be composed mainly of ureas and amides (Fig 
1.6). Typically, a stable peptidomimetic molecule is defined by the rigidity of the 
constituent  monomer units16, with conformational preferences given by the 
bonds that link the monomer units together. A peptide mimic that is mainly 
composed of oligoureas may have advantages over natural peptides.  
 
 
 
 
 
                   
           Figure 1.7.  S,S−1,2-diphenyl−1,2−diphenyl−1,2−diamine (A) 
           and its lowest energy conformer (B). 
 
 Some of these advantages include the following: oligoureas do not differ greatly 
from naturally occurring peptides in structure and this may allow the 
peptidomimetic to fold in a similar manner to the native peptides; oligoureas 
should not be susceptible to degradation, because ureases, enzymes that 
degrade urea bonds, are not as developed as peptidases. In addition to this, the 
backbone will allow stabilization of the secondary structure, via hydrogen 
bonding between the carbonyl oxygen and the hydrogen attached to the nitrogen. 
Also, secondary structures are stabilized by factors such as π−stacking, 
hydrophobic-hydrophilic interactions.17 In our case, having aromatic rings present 
in our molecules will allow π−stacking to occur. Secondary structure will show the 
conformation(s) of a given foldamer, defined in terms of four dihedral angles. In 
general, the most common secondary structures of a natural peptide foldamer 
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include α−helices, β−sheets, turns, and 
random coil. The α−helix, discovered by 
Pauling and Corey,18 is one of the most 
common secondary structural motifs, which 
contains residues that wrap themselves 
around a central axis in a regular pattern. 
α−Helices are stabilized by internal hydrogen 
bonds where the carbonyl bonds and 
amide/urea NH bonds lie parallel to helical 
axis with the carbonyls pointing downward 
towards the carboxyl terminus with amino 
groups pointing upward towards the amino 
terminus. In our case, the linkage of several 
C2 symmetric monomer units (Figure 1.8 - in 
their lowest energy conformer, in tandem with 
natural occurring amino acids) should be sufficient in producing a helical−like 
motif.  Also,     the main helix will be affected by any side chains, more 
specifically the geometry on the side chains, as well as, any functional groups 
that are present on those monomers. These side chains may enhance formation 
of secondary structures and allow the peptidomimetic to carry out interesting 
functions. One possible example of this is having a peptidomimetic imbued with 
side chains, possessing a positive charge, which allows interaction with 
negatively charged bacterial membranes to occur. Although these types of 
aspects are to be taken under consideration, one can not be sure of the outcome 
of the design. After all, nature does not follow the rules of man, so there’s a 
chance that the foldamers will not follow these rules as well, no matter how well 
they are planned.  
1.4 Conformational Aspects of Design 
1.4.1 Monte Carlo simulations 
Molecular modeling is used to predict conformation in molecules of 
interest, whether those molecules are natural or designed. Unfortunately, 
Figure 1.8. An oligourea 
foldamer 
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because of the way molecular modeling programs locate energy minima, the 
resulting structure from a conformational search may not be the lowest minimum 
energy conformer for the molecule (This will be explained shortly).  For molecular  
                     Figure 1.9. Monte Carlo conformational searching.  
   
modeling programs, the lowest possible energy conformation produced by the 
minimization process can be called the global minimum. In Figure 1.9, the global 
minimum shown is the deepest energy well. Also, local minima, (the smaller 
energy wells) are also important for conformation. In order to explore molecular 
conformations, we use Monte Carlo methods.19 Monte Carlo (MC) methods refer 
to any simulation of an arbitrary system which uses a computer algorithm 
explicitly dependent on a series of (pseudo) random numbers. The name, which 
derives from the famous Monaco city, emphasizes the importance of 
randomness, or chance (just like gambling), in the method. MC methodology is 
particularly important in stochastic analyses, where systems that have a large 
number of degrees of freedom and quantities of interest, such as thermal 
averages, cannot be computed exactly. The majority of minimization programs 
calculate energy derivatives at a particular conformation. Next, conformational 
variables are adjusted (based on the energy derivatives), allowing for rapid 
determination of minima. Using this method, the local minima are discovered if 
starting from points a or b in conformational space or from the global minimum if 
point c is the starting point (see Figure 1.9). Modeling software users defeat the 
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tendency to achieve local minima by intelligently choosing the starting points. 
(This is the main reason why we started with a helical-like motif having all 
carbonyls pointed in the same direction). Monte Carlo calculations simulate heat 
energy to explore the conformations of a molecule. The process works by 
applying a random change to a set of rotatable bonds, such as rotational 
increments between 0 and 360°, or via atom displacement.19 If no high-energy 
steric interactions are discovered, then a minimization calculation is run. The 
energy from this minimization calculation is compared to the energy of the lowest 
minima structure. If a minimum structure is found then this structure is adjusted 
and becomes the new starting point. If not, the Metropolis algorithm comes into 
play and provides a prescription for choosing which moves in conformational 
space to accept or reject.20 This algorithm works by randomly “strolling” through 
the conformational space of interest. This process is designed in such a way, that 
the points on the random “stroll” are distributed according to the required 
probability distribution.  At each point on this “stroll”, a random movement from 
the current position in conformational space is selected. This trial move is then 
either accepted or rejected according  to a  simple  probability given  by the  
Boltzmann  distribution  (Figure 1.10).21 If the  move  is  accepted  then  the    
          Equation 1.1 Boltzmann distribution equation. In the Boltzmann 
          distribution equation, A is a constant, g is degeneracy (the number  
          of states with identical energy) and k is equal to 1.38 x 10-23 J/K, 
          (Boltzmann’s constant). 
 
algorithm moves to the new position picked in conformational space; otherwise it 
remains where it is. Next, another trial step is then chosen, either from the new 
accepted position or from the old position. If the first move is rejected the process 
is repeated. In this way it should be possible for the exploration of all 
conformational space.  
N = Ag e-ΔE/kT
Equation 1.1
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1.4.2 AMBER 
The AMBER22 torsional parameterization set, employed with Macromodel 
(Version 8.0), was used to find the low energy conformers of the tetramers. 
Amber, consisting of a set of molecular mechanics force fields, is widely used for 
the computerized simulation of biomolecules. Amber, in a similar manner to the 
majority of molecular mechanics force fields, is quite dependent on variables 
which are experimentally determined. Molecular stability is conferred to the 
molecule when optimal bond angles, dihedral angles and bond lengths are 
reached. In addition to this, van der Waal forces are also employed as well.  
1.4.3 Solvent Effects 
Solvent effects play a tremendous role upon the relative energy of many 
materials in solution. The Macromodel program uses the Generalized 
Born/Surface Approximation (GB/SA) model to describe solvent effects.23 For the 
analysis of the tetramers, a CHCl3 parameter set was used. Solvent associated 
free energy, Gsol, is the sum of three independent terms23 (Equation 1.2) which 
are:  a solvent-solute polarization term, Gpol, a solvent-solvent cavity term, Gcav     
         Equation 1.2. This equation relates the free energy of a solvent, Gsol. 
         Gsol is related to 3 specific parameters which are  Gcav, GvdW and Gpol. 
 
and a solute-solvent cavity term, GvdW, For saturated hydrocarbons, Gsol is 
linearly related24,25 to the surface area which must be solvent accessible (SA). 
The terms GvdW and Gcav can be calculated by determination of solvation 
parameter and the surface area for each atom. The other parameter modifies the 
system’s electrostatic attractions. The generalized Born equation, described by 
Still, is used to relate the dielectric constant of the solvent to a contraction of both 
the attractive/ repulsive forces of two or more charges.23 
Gsol = Gcav + GvdW + Gpol
Equation 1.2
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1.4.4 Computational Foldamer Design 
Computation is a common point of 
departure for molecular design, especially 
in studying foldamer motifs. The actual 
ideas for this project originated from a 
different project in the Cammers’ lab, which 
through molecular modeling and CD studies 
of short oligoureas sequences derived from the molecule 
trans−1,2−cyclohexyldiamine (Fig 1.10), showed that the minimal energy 
conformation of the compound  trans−1,2−cyclohexyldiamine (Fig. 1.11) 
(Amber*/Macromodel 8.0) suggested that the molecule may be helical in 
solution.26 This also gave us an indication that the local symmetry of the 
monomer (C2) could be translated into global symmetry, forming a motif with 
residues placed periodically. Therefore, we expected a similar trend to occur in 
our compounds, even with the natural amino acid residues present. Performing 
Monte Carlo conformational searches on the two tetramer structures, Figs. 
1.12a−d (right-handed motif) and 1.12e−f (left-handed motif) with the force 
field, Amber/Macromodel 8.0, resulted in an energetic preference for a right-
handed helical-like motif, containing S,S− 1,2−diphenyl−1,2−diaminoethane units 
and a left handed motif composed containing 2 symmetric molecules with units of 
the R,R−1,2−diphenyl−1,2−diaminoethane. The CH3Cl continuum dielectric field27 
gave a more helical−like motif, but otherwise 
the results were similar to the calculations 
using the water solvent continuum. These 
computations were initiated from helical−like 
conformations, consisting of 12 monomer units, 
with all the urea carbonyls pointed in the same 
direction. Within a window of 25 kJ/mol (1000 
max iterations for each cycle), 48 possible 
lowest energy structures were found.  
     Figure 1.11.  Oligoureas.    
NH2
NH2
               Figure 1.10.  
trans−1,2−diaminocylohexane
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                          Figure 1.12a. S,S−tetramer (Rt. handed motif).  
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       Figure 1.12b.  S,S−tetramer (Rt. handed motif). Phenyl groups are on 
       the exterior of the motif.  
                                 (Hydrogen atoms removed for clarity) 
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   Figure 1.12c. S,S−tetramer. (Rt. handed motif) Most carbonyl units are 
   orientated towards one direction. 
                  (Phenyl rings and hydrogen atoms removed for clarity) 
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   Figure 1.12d. S,S−tetramer. (Rt. handed motif) Polar units are located in 
   the interior of the helical motif. 
                    (Phenyl rings and hydrogen atoms removed for clarity). 
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   Figure 1.12e. R,R−tetramer. (Lt. handed motif). Upon comparison with the 
  S,S−tetramer, the R,R−tetramer looks disordered. 
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Figure 1.12f, R,R−tetramer. (Lt. handed motif). Carbonyl units are orientated in 
many directions.  
                    (Phenyl rings and hydrogen atoms removed for clarity). 
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As evident from Figures 1.12 a−d, the helical-like motif comprised of units from 
S,S−1,2−dipheyl−1,2−diamine is more ordered. Also, this motif has the carbonyls 
pointing generally in the same direction, which allows for hydrogen bonding 
which leads to structure stabilization and positioning of the amino acid side 
chains preferentially on one side. However, the motif comprised of units from 
R,R−1,2−diphenyl−1,2−diamine, Figures 1.12 e−f shows that the motif is not 
ordered, does not have the lysine side chains positioned preferentially on one 
side of the molecule and its carbonyl groups are not orientated towards the same 
direction. 
1.5 Solid Phase Organic Synthesis  
1.5.1 Introduction  
Isolation of peptides from natural sources and solution phase synthesis of 
some types of polymers is often a tedious, time-consuming operation which often 
fails, leading to disastrous results. However, one way to make peptides is to 
clone the appropriate peptide from a gene in a suitable host. Still, this may be 
problematic due to the cost of the operation, isolation from the media used to 
grow the peptide and length of time. Plus, if one desired analogs of these same 
peptides, this would not be a good way to make them. Furthermore, peptides can 
not be readily isolated via expression. For other types of polymers, large scale 
reactions must be carried out in order to have abundant quantity of material to be 
used in subsequent steps. Fortunately, solid phase organic synthesis (SPOS) 
has provided a way to access these molecules of interest. In addition, various 
derivatives of these molecules can be made, leading to some intriguing and 
fascinating results. However, SPOS still has its problems and limitations. For 
example, in the realm of peptide synthesis, if one wanted to synthesize a peptide 
comprised of 25 different amino acids, some questions would have to be 
addressed first. How long would it take to make such a peptide? Would there be 
a point of diminishing returns? How could the peptide be purified? Are there any 
issues of solubility that needed to be addressed? Another problem could be 
epimerization at the activated C−terminus of an amino acid. Despite these 
problems there have been many successful solid phase syntheses, including the 
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enzyme, reverse transcriptase, which is responsible for replication in the human 
immunodeficiency virus.  
1.5.2 Principles of Solid Phase Synthesis 
The methodology behind SPOS, first developed by Bruce Merrifield28 in the 
1960’s to synthesize peptides, was not fully appreciated by chemists at first, but 
slowly began to be accepted as a good way to synthesize oligomeric 
compounds, such as peptides. Today, SPOS is a major tool in the synthetic 
chemists’ armory for the generation of purified organic molecules of all types.29 
The principle of SPOS is simple and straightforward. SPOS consists of the 
tethering of a substrate to an insoluble polymer matrix (mainly either composed 
of polystyrene or PEG) solid support. A growing chain whether it be a peptide, 
nucleotide or any other foldamer molecule is attached to this stable solid support 
by a linker, which keeps the molecule of interest attached to the solid support 
throughout all of the synthetic steps. Each reaction can be driven to completion, 
in theory by using an excess of reagents. Excess reaction materials and solvents 
are simply washed away by simple filtration. Finally, after assembly is complete, 
the desired product is removed from the solid support through different methods 
depending on the type of linker used. There are definite advantages to solid 
Figure 1.13. General Principle of Solid Phase Synthesis. 
a).    Shows reaction vessel containing solvent, reagent and resin. 
b).    Attachment to resin and eventual removal of excess reagents. 
c).    Reaction vessel containing only resin with attached substrate. 
a b c
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phase synthesis over conventional 
(solution phase) synthesis. These 
advantages include: shortened time 
periods, especially if an automated 
process is used, ease of purification, 
not being labor intensive and by 
keeping the beads from being filtered away in each reaction step, physical loss of 
material is not encountered. Since soluble reagents can be easily removed by 
filtration, large excesses of reagents can be used, encouraging high efficiency in 
the various chemical steps. Of course, where there are advantages, there are 
disadvantages as well. These disadvantages include: the efficiency of coupling 
reactions; being able to accurately monitor the reaction by conventional 
techniques such as TLC (However, the reactions can be monitored by NMR, 
FTIR); production of insoluble material and accumulation of the growing peptide 
chain, which could block or slow down the progress of a reaction. The coupling 
reactions must be efficient, simple to carry out and produce the product in good 
yield. Despite these difficulties solid phase synthesis has become one of the 
premier ways of synthesizing molecules of biological and structural importance. 
1.5.3 Choosing a Solid Support  
One of the most important aspects of SPOS is having and utilizing the correct 
solid support for the ultimate attachment of material (via a linker). Solid supports, 
as stated earlier, are composed of cross-linked polystyrene (and derivatives) or 
PEG (and derivatives). Cross-linking imparts mechanical stability, improved 
structural integrity and enhancement of the resin’s swelling properties.30 If the 
support is not cross-linked, the polymeric chains will fall-apart under 
thermodynamic conditions. In 
general, there are some 
requirements needed for an ideal 
solid support. These 
requirements include: having 
enough reactive sites where the 
Figure 1.15. Non-cross linked polystyrene.
May fall apart if certain conditions are met. 
Figure 1.14. Cross-linked  polystyrene 
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polymer chain can be attached and later removed; allowing for unhindered 
contact between the growing polymer chain and the reagents; being separable 
from the liquid phase at any part of the synthesis; being physically stable to 
reaction conditions and finally the support must minimize the interactions 
between bound polymer chains. Other things that must also be taken into 
consideration are the swelling properties of the solid support. If the polymer does 
not swell sufficiently, the substrates and solvents cannot permeate through the 
solid support. One last important factor is the size of the solid phase operation 
itself. Of course, as the size of the resin increases, more material can be loaded 
on it. However, one must take into consideration that there is a relationship 
between the size of the resin and how efficient material can diffuse through the 
polymer matrix (Fig. 1.16). 
Diffusion Efficiency
Tenta-Gel (90 μm) Polystyrene (200 μm) Polystyrene (500 μm)
 
       Figure 1.16. Solid Phase Resins. This figure shows a few of the different 
       sizes of solid phase resins and well as their diffusion efficiency. 
 
X
solid phase
    resin
solid phase
    resin
solid phase
    resin
linker linker
linker
attachment
molecule molecule
synthetic
   steps
cleavage
   step
molecule  
             Figure 1.17. Process on use of a linker. The linker is a conduit 
             for attachment of the molecule to the solid support. 
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1.5.4 Choosing a Linker Molecule 
After choosing the correct solid support, one must connect the potential substrate 
to this support. The best way to accomplish this is by using a “linker” molecule. A 
linker is a molecule that covalently connects the growing polymeric chain to the 
solid support providing a means for chemical attachment and cleavage31 (Fig 
1.17). Linker stability has a direct impact on the types of chemical reactions that 
can be employed on the solid phase. Solid phase linkers are quite diversified, 
ranging from linkers that break apart from the target substrate via nucleophilic 
reactions32 to linkers that decompose on exposure to light.33     
1.5.5 Fragment condensation 
         Figure 1.18. Amino acid Racemiztion.  This figure shows how an amino 
         acid can racemize under basic conditions. 
 
 
There are two types of methods for synthesizing foldamers, whether by a solid-
phase approach or solution synthesis. One method involves stepwise elongation, 
in which the monomers are connected step-by-step in turn. The other approach 
is the fragment condensation method, in which fragments (composed of several 
units) are coupled to each other. There are a few problems encountered while 
utilizing a step-by-step approach to the SPOS synthesis of foldamers. Some of 
these problems include: obtaining a lower overall yield by having the material go 
through many different reactions, especially protection and deprotection steps; 
the length of time involved for doing a multitude of reactions and the high 
likelihood that racemization may occur if a peptide or any monomer that has a 
possibility of becoming racemized (Figure 1.18). Fragment condensation34 is 
better than stepwise elongation, especially for the synthesis of sophisticated 
and/or lengthy foldamers. Fragment condensation strategies enhance the overall 
yield and purity of a foldamer by reducing the number of coupling and 
deprotection steps required during the course of the synthesis, relative to the 
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sequential strategy. In addition, the time involved in the synthesis would be lower 
and if one has peptides, the chances of having racemization occur would be 
lower. In addition to this, as oligoureas get longer it becomes more difficult to 
chemically differentiate an oligomer with n residues from an oligomer with (n+1) 
residues. 
1.6 Conclusion 
 Peptides, short sequences of amino acids have various roles in our body 
and are implicated in certain disease process. Peptides can also be used as 
novel drug candidates to treat diseases such as arteriosclerosis, Alzheimer’s 
disease and others. Unfortunately, therapeutic peptides have problems 
associated with their use, such as degradation, immunogenicity and absorption. 
Fortunately, peptide mimics can be made by modification of the backbone 
structure, as well as the inclusion of non-amino acid segments. These 
modifications must allow the newly created peptidomimetic to adopt a similar 
folding motif (foldamer) to the native peptide, giving the mimic similar abilities to 
the native peptide. Molecular modeling provides a good template to predict 
conformations in molecules of interest. Molecular modeling programs attempt to 
find the lowest possible energy for a structure. Unfortunately, the lowest energy 
conformer that is found may be a localized molecule and not the absolute lowest 
energy molecule possible. One of the methods molecular modeling programs use 
for searching conformational space is by use of Monte Carlo calculations. These 
Monte Carlo calculations attempt to simulate heat energy, by applying random 
change to rotatable bonds. Conformations are accepted or rejected by this 
process according to simple probability. Solution phase reaction of small 
peptides is tedious, time consuming and often lead to deleterious results. 
Fortunately, solid phase synthetic techniques eliminate some of the problems 
associated with solution phase chemistry. Solid Phase Organic Synthesis 
(SPOS) principles are rather simple, involving attachment of a substrate to a 
solid support; using an excess of reagents to drive reactions to their completion 
and then finally removal of the desired molecule from the solid support. There are 
two approaches to doing reactions on the solid support. One way, is by fragment 
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condensation, while the other approach is simply a linear step by step synthesis. 
The fragment condensation approach is preferred, allowing for fewer coupling 
steps, in comparison to the linear approach. This results in higher yields, 
shortened synthetic time and minimization of racemization. Also, the impurities 
produced in the linear synthesis will have oligomers with n and (n+1) residues. 
However, the oligomer product generated from fragment condensation will have 
oligomers with m, n and (m+n) residues. Therefore, oligomers generated from 
the fragment condensation approach should be easier to purify when compared 
to the oligomers generated by a linear step by step method. 
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Chapter 2 
Brief Review on Cationic Peptide Antibiotics 
 
2.1 Introduction to Brief Review of Cationic Antibiotic Peptides  
In chapter 1, it was discussed how peptides could be used as drugs, including 
their use as antibiotics. There are some common features in cationic antibiotic 
peptides, herein referred to as CAPs, which can be simulated in peptidomimetics. 
But first, a brief review on the different types of CAPs, some proposed 
mechanisms of action and a few bacteria defense mechanisms against CAPs is 
necessary to understand why the parameters mentioned in chapter one would be 
useful in the peptidomimetic. 
The antibiotic era began more than 70 years ago resulting from the 
discovery that a Penicillin mold inhibited the growth bacteria on bread. From this 
discovery, led to one of the greatest advances in medicine and with the use of 
antibiotic therapy many, many lives have been saved. Unfortunately, misuse of 
antibiotics has contributed to the production of resistant bacteria. Fortunately, it 
has been found that organisms, than span every kingdom and phylum, produce 
cationic peptides which possess antibiotic activity.35  
These peptides may have been progenitors of the first immune system and are 
quite diverse. CAPs have selective activity against both Gram-positive and 
Gram-negative bacteria and other pathogenic organisms. The vast majority of 
CAPs destroy bacteria by pore formation and/or by destruction of bacterial 
membranes.36,37 CAPs share several items in common, despite their diversity. 
Some of these items include: being composed less than 100 amino acid 
residues38; having an overall positive charge between +2 and +7 and possessing 
amphipathicity (this means that one face of the peptide is cationic, the other side 
hydrophobic).35 The peptide’s nature and the nature of target bacterial cells help 
to control the actions of all CAPs. Several scientists believe that CAPs work by 
the following process(es). First, an electrostatic attraction between the peptide 
(which is positively changed) and the cell membrane of the bacteria (negatively 
charged) occurs. When contact with the cell membrane is made, pores are 
created or the permeability of the cell membrane increases. Both pore creation 
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and increased permeability leads to loss of integrity of the bacterial membrane 
and eventual leakage of intracellular contents, causing the death of the bacterial 
cell. However, the exact mode(s) of action is (are) not known. Various models to 
explain these phenomena have been hypothesized to explain the mechanism of 
CAPs. These models include: The Barrel-stave model, Carpet model, Toroidal 
Pore model and Aggregate model.39-41 Because of their different mechanisms of 
action, diversity and variability, CAPs are currently being considered as an 
attractive replacement and supplement as well, to the current armory of 
antibiotics.  
2.2 Cationic Antibiotic Peptides and their Biological Activity  
Bacteria, both gram-positive and gram-
negative, possess a negatively charged 
cell membrane in common. Interestingly; 
some CAPs display broad spectrum 
activity against only Gram negative 
bacteria. Others CAPs attack only on 
Gram positive bacteria. The reason why 
CAPs display this versatility is due to the 
cell membrane differences between 
both gram-negative/gram-positive 
bacteria (Figure 2.6 and Figure 2.7). 
Fortunately, red blood cells 
(Erythrocytes) tend to be relatively 
resistant to CAPs, due to the very small 
negative potential on erythrocyte cell 
membranes. Some CAPs found in 
venoms, such as Melittin (bee venom)42, 
Mastoparan (wasp venom)43,44 and Cobatoxin (scorpion venom)45 can attack and 
destroy red blood cells.  
Figure 2.1. Magainin. The 
antibiotic peptide found in the 
African clawed frog. Lysine 
residues (shown) are responsible 
for peptide attraction to biological 
membranes. 
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G-I-G-K-F-L-H-S-A-K-K-F-G-K-A-F-V-G-E-I-M-N-S
         Chart 2.1. Magainin Amino Acid Sequence
2.3 Cationic Antibiotic Peptides and their Diversity  
CAPs have been discovered in all types of plants and animals (more than 
800, at this time). Due to the molecular diversity of CAPs, the best way to 
categorize them is to place the CAPs in four distinctive groups by their secondary 
structure commonalities (van’t Hof method).46 
2.3.1 α−Helical Cationic Antibiotic Peptides 
Peptides which have a structure are the largest class of cationic antibiotic 
peptides. α−helical peptides are found in all types of organisms and have been 
the most studied class of CAPs at this time. In general, these CAPs stay 
disordered until contact with lipid surfaces occurs. Upon contact with these lipid 
surfaces, these peptides will fold into a α−helical motif. The most famous 
α−helical peptide and also the most studied is Magainin (Figure 2.1), a 23 
residue peptide (Chart 2.1) from Xenopus laevis, the African clawed frog. Other 
members include Cecropin A, which is found in wasps and the interesting Melittin 
(Figure 2.2), the major constituent of bee venom that causes destruction of red 
blood cells. α−helical cationic antibiotic 
peptides depend on several factors 
which define their activities. These 
factors include: degree of helicity, 
Hydrophobicity, cationic charge and 
amphipathicity. Let’s discuss these 
parameters in some detail. Helicity: 
Helicity is an important factor for 
antibiotic activity because it allows the 
creation of both a cationic and 
hydrophobic face, which is necessary 
for initial attraction to membranes and 
eventual membrane insertion itself. 
Figure 2.2. Melittin. The major 
peptide constituent of bee venom. 
The basic side chains are mainly on 
one side of this peptide, causing 
Melittin to have hemolytic activity. 
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However, some α−helical CAPs such as Magainin lose their antibiotic activity 
when certain D−amino acids are present in the peptide. These D−amino acids 
prevent Magainin folding into a helical motif. Amphipathicity: Amphipathicity is 
simply the measurement of the distances between both the hydrophilic and 
hydrophobic sides of a peptide. Amphipathicity is measured by the hydrophobic 
moment, which calculates the likelihood that a peptide residue will be located 
between hydrophobic and hydrophilic regions.47 Hydrophobicity: Hydrophobicity 
measures the strength of peptide attraction for cell membranes and does not 
depend on the charge, as well as amphipathicity of a particular peptide. Polar 
angles: Polar angles are the angles that lie between the hydrophilic and 
hydrophobic peptide faces. These angles are one major controlling factor that 
modulates the way CAPs attach to membranes. CAPs that are highly 
hydrophobic, containing small polar (hydrophilic) angles tend to create pores 
through the cell membrane. Charge: CAPs are positively charged (between +2 to 
+9) due to the basic amino acid side chains (lysine and arginine). Peptides 
containing net positive charges (in this range) attach themselves to the target 
bacterial membrane (which is neg. charged). However, if the net positive charge 
is too high, peptide activity decreases due to the charge repulsion that occurs at 
the site of attachment.   
2.3.2 Linear Cationic Antibiotic Peptides with Unusual Composition  
Linear CAPs are peptides that have over-abundance in one or more amino acids. 
One example of this is Indolicidin. A 13 residue, tryptophan containing peptide, 
(Chart 2.2) and (Figure 2.3).48 Initially, it was thought that Indolicidin adopted a 
helical conformation49, similar to other peptides, but CD studies show that 
Indolicidin adopts a different conformation instead. This conformation consists of 
a turn, which is believed to enhance Indolicidin’s membrane activity.50 Indolicidin 
is also believed to work by targeting nucleic acids blocking replication of the 
H-Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Arg-Arg-NH2
                        Chart 2.2. Indolicidin Sequence
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bacteria.51 Other members in this family of peptides include  histatin52, attacin53 
and tritrpticin.54 
 
 
 
 
 
 
 
 
Figure 2.3. Indolicidin. An unusual                  Figure 2.4. Bactenecin. A looped 
antibiotic peptide containing the amino              antibiotic peptide, highly rich in  
tryptophan (residues shown).                             proline. Basic side chains are 
                                                                           responsible for activity. 
 
 
 
 
 
 
 
 
                       Figure 2.5. Defensin. A complex antibiotic 
                       peptide found in mammals, such as humans 
                       and rabbits. Side chains responsible for 
                       peptide activity are shown. 
 
2.3.3 Looped Peptides  
Bactenecin (Figure 2.4), from bovine neutrophils55, is the smallest natural CAP 
being only 12 amino acids long. Bactenecin also contains two cysteine residues 
capable of forming a disulfide bond. This disulfide bond allows Bactenecin to 
have a loop in its structure. Upon removal of the disulfide bond, this peptide 
possesses no activity against bacteria.56  So, this disulfide bond is responsible for 
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maintaining the peptides structural integrity. Other members in this family of 
peptides include brevinin-157, brevinin-257 and thanatin.58 
2.3.4 β−sheet Peptides containing Intramolecular Disulfide Bonds 
Unlike other peptides, β−sheet peptides are simply cyclic peptides which are held 
together by a few disulfide bonds. One example of these types of peptides are 
the Defensins (Figure 2.5), which are the principal constituents of cytoplasmic 
granules of mammalian neutrophils and certain macrophages. Defensins are one 
of the most studied β−sheet antibiotic peptides. Also, some studies show for 
activity to occur for these CAPs, the disulfide bonds must be present. Other 
members in this family include Tachyplesin and Gomesin.59 
2.4 Cationic Antibiotic Peptide Specificity for Certain Cells 
One of the unique properties of most CAPs is their specificity to destroy bacteria, 
while remaining relatively non-toxic to eukaryotic cells. The reason for this is due 
to differences that are present in bacterial and mammalian cell membranes.60,61  
One difference between the two types of cells is the presence of 
lipopolysaccharides (LPS) in Gram-negative bacteria and teichoic acids in gram-
positive bacteria. LPS plays an important role in bacterial toxicity by causing 
sepsis in humans. Lipopolysaccharides are located on the outermost surface on 
these bacteria (gram-negative) (Figure 2.6). For Gram-positive bacteria (Figure 
2.7), acidic polysaccharides (teichoic acids) are also found on the outermost 
surface of the bacteria. Having either LPS or teichoic acids on the bacteria 
surface gives bacteria a net negative charge. In addition to this, the 
phospholipids that are present in bacterial cell membranes are also negatively 
charged, thus increasing the net negative charge for the bacteria. On the other 
hand, the typical mammalian cell is mainly composed of zwitterionic 
phospholipids, therefore the typical mammalian cell is not as negatively charged 
upon comparison with bacteria.  
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Figure 2.6. Gram negative bacteria            Figure 2.7. Gram positive bacteria   
cell wall. The  LPS (orange) provides           cell wall. Teichoic acid (green) is             
the virulence factor for this bacteria,              provides the negative charge which 
as well as the negative charge                       is needed for antibiotic peptide  
needed for antibiotic peptide activity.             activity. 
 
2.5 How do Cationic Antibiotic Peptides Work?  
The various effects of cationic antibiotic peptides (CAPs) eventually 
results in disruption of cellular structure and/or function. Also, CAPs adopt similar 
themes in activity, regardless of size, source, composition or conformation. The 
activity of these peptides begin by initial attraction to the target via biochemical or 
biophysical affinities, (i.e. negatively charged bacteria membranes) or by self-
promoted uptake. After the initial attraction has taken place, the peptide makes 
contact with the bacterial membrane where conformational changes begin to 
occur. A great example of this is Magainin. As stated earlier, Magainin exists, in 
aqueous solution, as a random coil and folds into a helical motif upon interaction 
with bacterial membranes. One great aspect about conformational change is that 
it only occurs after the peptide interacts with appropriate target. This is important 
because it allows the peptide not to be active against a “friendly” cell. Next, 
peptides begin to accumulate in the cytoplasm and also on the bacterial 
membrane. After the appropriate amount of peptide has interacted with the 
membrane, peptides insert and eventually destroy the bacterial membrane, 
leading to leakage of cellular contents and cell death. In addition to this, after 
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entering the interior of the cell, CAPs seek out and disable specific intracellular 
components, making them non-effective. Several models have been theorized to 
explain how CAPs work. Due to the different compositions and the environment 
of bacteria membranes, a CAP can work by different modes of action, sometimes 
simultaneously or in tandem. The following four models have been presented to 
explain the mechanism of cationic antibiotic peptides.  
2.5.1 The Barrel-stave Model 
In the barrel-stave model (Figure 2.8) CAPs line up in a ring-like manner 
forming a pore (This would be the top of a barrel). The “stave” refers to 
transmembrane spokes within the barrel, where the spokes consists of individual 
peptides or peptide complexes. After additional peptides are attracted to the 
membrane, an increase in the overall pore size occurs. This eventually causes 
cell death by leakage of intracellular components out these newly created pores.  
 
Scientists believe that CAPs position themselves in such a way that their 
hydrophobic side chains interact with the lipid environment of the bacterial 
membrane, while the polar side chains are aligned inward forming 
transmembrane pores. This process is driven mainly by hydrophobic interactions 
with the bacterial membrane. However, if the peptide has a high net positive 
charge (from basic side chains) it is unlikely that bacterial destruction will occur 
by this mechanism due to repulsion arising from electrostatic interactions. 
 
Figure 2.8. Illustration of the Barrel Stave Model. Antibiotic peptides are 
attracted to and coordinate themselves to the surface of the bacteria. (A) 
Peptides insert themselves into membrane as staves (B) allowing for leakage 
of cytoplasmic material. 
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2.5.2 The Carpet Model 
Figure 2.9. Illustration of the Carpet Model. Antibiotic peptides are attracted to 
and coordinate themselves to the bacterial surface (A). Peptides randomly insert 
themselves into the membrane (B). When a threshold concentration of peptides 
is reached, the bacterial membrane disintegrates, leading to bacterial death (C).   
 
In the beginning, it was assumed that all CAPs kill bacteria by the creation of 
membrane pores through the barrel-stave model process. However, the 
interaction of Magainin and other CAPs, with membranes did not work by the 
‘barrel-stave’ model. Therefore a different model called the carpet model (Fig. 
2.9) was described and proposed40. According to this model, CAPs are initially 
attracted to the bacterial membrane by an electrostatic attraction. Next, the 
peptides aggregate on the surface and eventually coat the bacterial membrane 
until the surface is completely covered with peptides. Unlike the barrel-stave 
model, peptides do not penetrate the membrane. Instead peptides remain in 
contact with the membrane leading to membrane disruption, leakage of 
cytoplasmic contents and finally, total membrane destruction, itself. The peptides 
that work via the carpet model have a high net positive charge and do not bind 
strongly to bacterial membranes. Therefore, peptides that utilize the carpet model 
to destroy bacteria have the following propensities: A high net positive charge as 
well as the ability to not bind strongly to cell membranes. 
 
 
A
B C
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2.5.3 The Toroidal Pore Model 
Figure 2.10. Illustration of the Toroidal Pore Model.  Antibiotic peptides are 
attracted to and coordinate themselves to the bacterial surface (A). Peptides 
randomly insert and integrate themselves into membrane opening a pore in the 
bacteria, which allows intracellular contents to leak out, resulting in cell death (B). 
 
The Toroidal Pore model (Figure 2.10) initially begins quite similar to the 
previously mentioned carpet model, but midway in the process, the cationic 
antibiotic peptides form a toroidal pore. These toroidal pores allow leakage of 
small cytoplasmic molecules prior to complete destruction of the bacterial 
membrane. Unlike barrel-stave pores, toroidal pores consist of peptides 
intercalated with the cell membrane. Experiments with Magainin63 and Melittin64 
show the toroidal pore model is the principle model by which CAPs attack 
bacteria cell membranes. The toroidal pore mechanism suggests that α−helical 
CAPs initially lie parallel to the bacterial cell membrane. In the next step, the 
hydrophobic portion of peptide inserts itself and displaces the polar portion(s) of 
the membrane. This process leads to peptide insertion into the membrane.65 
When enough CAPs have inserted themselves into the membrane, strain and 
membrane thinning begins to take place. The ultimate result of this membrane 
thinning is the destabilization and eventual membrane destruction.66 Finally, the 
CAPs, now in the cytoplasm, begin to attack intracellular targets rendering those 
targets useless.67  
2.5.4 The Aggregate Model 
It has been noted that some CAPs have bactericidal activity without significantly 
destroying or altering the bacterial membrane. The models which were previously 
mentioned are unable to explain why certain peptides are able to destroy 
bacteria by shutting down DNA synthesis; protein inhibition or receptor 
interactions. Due to these interesting findings another model named the 
Aggregate Channel was proposed.41 This model suggests that CAPs cluster 
together in a more or less random fashion on the surface of the bacterial 
A B
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membrane, capturing small negatively charged ions or water molecules. This 
leads to electrostatic repulsion between the positively charged amino acid side 
chains. Peptides cluster together and migrate throughout the bacterial membrane 
without causing major damage to it. The result of this is membrane local 
destabilization and peptide migration into the cytoplasm. It is assumed that the 
CAPs (now in the cytoplasm) attack specific intracellular targets and turn off 
cellular functions. Cationic antibiotic peptides can work by any mode of action. 
However, some CAPs may work by just one or perhaps many different 
mechanisms. This depends on the target bacterial cell of interest and of the CAP 
itself. The good news is that the end result of any of the aforementioned 
processes, the disruption of bacterial membranes, eventually leads to destruction 
of the target bacterial cell. 
2.6 Cationic Antibiotic Peptides and Bacterial Resistance  
Bacteria are tough little organisms that can survive in diverse places ranging 
from the cold of the ocean depths to desert hot springs. Therefore, it is realistic to 
expect that some bacteria would be resistant to CAPs. There are two types of 
resistance bacteria can have and it is not understood at the molecular level why 
some bacteria have immunity towards CAPs. One reason for this could be that 
some bacterial membranes may not contain enough negative charge or repel the 
peptide itself, due to a mutation. Also, outer cell membrane structural 
modifications (Gram-negative bacteria) have also been theorized to help bacteria 
become resistant to CAPS.68  
2.6.1 Passive Resistance - Membrane Energetics 
Some antibiotic peptides work by using the transmembrane potential of bacterial 
membranes as a driving force. Therefore, transmembrane potential can be 
regulated blocking the efficacy of CAPs. For example, one class of defensins 
(type-I) exert comparable antibiotic activities against bacteria that is either 
metabolically active or in a resting state.69 However, a different class of defensins 
(type-II) exerts antibiotic potency against only metabolically active bacteria. This 
shows that certain bacteria which have low transmembrane potential, will have 
significant resistant against cationic antibiotic peptides. 
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2.6.2 Shielding by Electrostatic Interactions 
A lot of pathogenic bacteria rely on encapsulation to prevent phagocytosis from 
immune system cells or just to adhere themselves to a preferred location. 
Capsule production is also an important, particularly among bacteria that infect 
the bloodstream, gastrointestinal and respiratory tracts. The glycocalyx 
(capsulation material) of many pathogenic bacteria is composed both 
carbohydrates and phosphates. Since the glycocalyx is negatively charged, 
CAPs are attracted to it and upon contact with this anionic material, CAPs 
become incapable of reaching the membrane, rendering them ineffective.70 
2.6.3 Region Specific Resistance 
Some pathogenic bacteria are able to resist CAPs, due to preferences for certain 
anatomical or physiological regions. One example of this is Pseudomonas 
aeruginosa, a class of bacteria responsible for urinary tract infections. These 
bacteria preferentially colonize tissues, such as the bladder and stomach which 
have abnormal ionic strength and/or abnormal osmotic pressure. The 
environment of these colonized tissues helps to prevent attack from antibiotic 
peptides.71 
2.7 Inducible Resistance 
Many pathogenic bacteria have evolved to produce successful counter defenses 
intended to block the effectiveness of cationic antibiotic peptides, which must be 
defeated for the pathogenic bacteria to survive and multiply. Some of these 
countermeasures range from permanent modification of the bacteria membrane 
and well as activation of toxic factors.  
2.7.1 Defense via Peptidases 
Probably one of the easiest ways bacteria defend themselves against cationic 
antibiotic peptides is through the secretion of peptidases that attack and destroy 
CAPs. One example of this occurs in the Salmonella species of bacteria. 
Salmonella has the ability to produce outer membrane endopeptidases, for 
example, which are able to attack and degrade CAPs.72 
 36
2.7.2 Structural Modifications to the Outer Membrane 
As stated earlier, cationic antibiotic peptides (CAPs) initially target and interact 
with bacterial components, such as LPS, outside the cellular membrane. 
Evolution has provided bacteria with feedback systems that are utilized to 
prevent its destruction by CAPs. These feedback systems are rapidly induced in 
response to exposure to cationic antibiotic peptides. For example, CAPs can 
influence gene activation in Salmonella bacteria. This gene influences changes in 
the transmembrane gradient of the bacteria, which blocks CAPs from 
working.33,74 Also, Gram-negative bacteria have the ability to modify its lipid A 
and LPS components leading to increased resistance to CAPs.68,75 
2.7.3 Cytoplasmic Membrane Modifications  
Another type of modification pathogenic bacteria can use to block CAPs activity 
is by changing their cytoplasmic membrane composition. One example, comes 
from the species, Pseudomonas fluorescens (colonizes both soil and plant 
surfaces). If there aren’t enough phosphate sources available, this species has 
the ability to lose their negative cell potential, by modification with ornithine 
derived lipids, which are positively charged, leading to a decline of CAP activity 
towards this bacteria.76  
2.7.4 Attacking Intracellular Components 
Besides attacking extracellular components, CAPs also have the ability to attack 
intracellular targets. Bacteria have also devised mechanisms to prevent this from 
occurring. One species of E. coli, shows that mutation in one gene (named gyrB), 
led to significant decline of the bacteria being destroyed by the antibiotic peptide 
microcin B17, which is thought to block DNA replication (DNA gyrase). 
Specifically, E. coli’s mutation causes an arginine residue to replace the normal 
tryptophan residue found in the polypeptide produced by the gyrB gene. This 
change leads to the reduced activity of microcin B17. Due to these recent 
findings, researchers are now aware that cationic antibiotic peptides can exert 
other actions, such is targeting internal components that goes beyond just simple 
interactions with the bacterial cell membrane.77  
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2.8 Conclusion 
Widespread use/abuse of antibiotics, such as penicillin, erythromycin and 
others has led to a situation where pathogenic bacteria are becoming resistant to 
antibiotics. Organisms from divine phyla have evolved antibiotic mechanisms that 
generally involve the production of cationic antibiotic peptides with varying 
antibiotic activity. CAPs are found in various organisms and may be the first 
progenitor to an early immune system. Cationic antibiotic peptides (CAPs) are 
quite diverse, ranging from α−helices to constrained sheets, but all share certain 
commonalities such as a moderately high positive charge, less than 100 residues 
and amphipathicity. CAPs have high activity against bacteria in addition to 
possessing low activity towards mammalian cells. The mechanism(s) of action 
used by CAPs is (are) not known, but several models such as the Carpet, Barrel-
Stave and Toroidal have been hypothesized to explain peptide activity. 
Unfortunately, bacteria possess resistance to these peptides through different 
methodologies. Some of these methods are simple such as hiding in a specific 
location in the host to complex such as gene modification to provide resistance.  
2.9 Notes 
Notes: Figures 2.1 - 2.5 were created by obtaining the peptide sequence from 
various sources, then drawing and minimization with Macromodel and finally 
resolution with the drawing program, Pov-ray. 
Figures 2.6 and 2.7 are copyright of Peter Sforza (psforza@vt.edu) 
Figures 2.8 and 2.9 are copyright of Yechiel Shai  
(Yechiel.Shai@weizmann.ac.il) 
Figure 2.10 was created by modification of Figure 2.9 
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                                                        Chapter 3 
General Syntheses of Compounds 
 
3.1 Synthesis of (S,S) and (R,R)−1,2−Diphenyl−1,2−Ethylenediamine 
 
 
 
 
 
 
 
 
 
The compounds (S,S) and (R,R)−1,2−diphenyl−1,2−ethylenediamine (DPDA) and 
its derivatives have been used as chiral controllers and chiral catalysts in many 
asymmetric reactions78-81 (Figure 3.1). There are various approaches one can 
use to synthesize either enantiomer of DPDA. Some of these synthetic routes to 
the both diamine enantiomers include: manipulation of the chiral diol from styrene 
using Sharpless asymmetric dihydroxylation protocols82 (Scheme 3.1); the 
titanium  mediated  coupling  of  two  simple  imines  derived  from  benzaldehyde81,  
 
 
 
 
 
 
 
 
        Scheme 3.1. Sharpless approach to enantiomerically pure DPDA.  
 
Figure 3.1. Two enantiomers of DPDA
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then resolution leading to both enantiomers of DPDA (Scheme 3.2) and a 
protocol by Mistryukov, where a hydrobenzamide was converted to a d,l -DPDA 
precursor by an electrocyclic ring closure83 (Scheme 3.3). 
 
 
 
 
 
 
 
 
               Scheme 3.2. Titanium mediated coupling. 
 
One of the problems with the Sharpless approach to DPDA (which is actually a 
known procedure) is the use of toxic OsO4 on a scale needed to obtain a large 
amount of product and the extra steps needed to convert the chiral diol to the 
diamine itself.  Although the titanium method works fairly well, on a small to 
moderate scale, it produces the meso product (15 %) which first has to be 
removed before resolution can take place. Mistryukov’s approach, albeit novel, 
has some drawbacks associated with it, such as: the use of mercury salts and 
the use of a pressure bomb to make the appropriate intermediates.  
 
 
 
 
 
 
 
 
 
                              Scheme 3.3.  An electrocyclic ring closure.                     
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The preferred approach, the one we used, involved synthesis of the racemic 
diamine (d,l isomers only), then resolution by the appropriate tartaric acid, into 
pure enantiomers.84 The materials used in this synthesis are extremely cheap 
and easy to obtain, which is an advantage. The synthesis begins by the reaction 
of a mixture of cyclohexanone, benzil, ammonium acetate refluxing in acetic 
acid.  
                    
 
 
 
 
 
                    Figure. 3.2. Dianion formed from Lithium Reduction. 
 
 
 
 
 
 
                               
                           Scheme 3.4. Synthesis of Spiro-imidazole    
3 
This type of synthesis has been used in the middle of the 20th century as a 
method of producing various heterocyclic compounds85 and in this particular 
case, resulted in the formation of the spiroimidazole compound, 3, in good yield84 
(Scheme 3.4). One of the more noteworthy items about this reaction is that it can 
be done on a very large scale (easily up to 1 kg). Next, lithium metal was used to 
reduce both double bonds in the spiroimidazole, 3. Four 
moles of lithium were needed, because lithium donates 
one electron per pi bond, which eventually resulted in the 
formation of a dianion (Figure 3.2). Spiroimidazole, 3, is 
fused together; therefore no free rotation is allowed. The 
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newly formed anions seek to oppose each other due to electron repulsion 
(Figure 3.2), giving rise to a lower energy intermediate and upon protonation to 
produce only the d,l product, 4. Spiro ring opening was accomplished by using 2 
N HCl and upon basification with NaOH led to the racemic diamine. Finally, the 
d,l isomers were resolved with tartaric acid, where  L-(+)-tartaric acid gave rise to 
the S,S-isomer and D-(-)-tartaric acid gave rise to the R,R isomer84.  
3.2 Diamine Mono-protection Strategies 
 
 
 
 
 
                        Scheme 3.5.  Synthesis of Mono-Boc DPDA 
 
At this point the DPDA needed to be protected, due to the eventual coupling of 
two separate DPDA molecules in a future step. Since the DPDA molecule 
possesses C2 symmetry, orthogonal protecting groups must be used in this 
situation. 
 
 
 
 
 
 
 
 
 
                         Scheme 3.6.  Synthesis of Mono-TFA DPDA  
 
At first, we thought the easiest mono-protected diamine to synthesize would be 
the BOC mono-protected diamine. In general, mono-protection of vicinal primary  
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diamines is quite problematic, usually resulting in protection of both diamines. An 
attempt to synthesize a mono-Boc diamine was made, by carefully reacting 1 
equivalent of BOC anhydride with the DPDA in DCM (Only the S enantiomer was 
tried). The yield of this reaction is quite low, which is characteristic of vicinal 
diamine mono-protection, with the majority of the product being the diprotected 
material. The literature shows that DPDA, (both enantiomers, respectively) can 
be mono-protected by using ethyl trifluoroacetate (excess amount) in THF 
affording 100 % yield of the mono-protected TFA compound.86  In a similar 
manner, this was attempted using DCM as the solvent, instead of THF. This 
reaction still worked as the literature suggested. The authors of the paper gave 
no explanation why this reaction led to the mono-protected TFA amine. One 
hypothesis could be that the molecule undergoes a reversible cyclization (Figure 
3.3) where the amino group attacks an electron poor carbonyl group in the same 
molecule leading to a 5-membered ring hydrate at low temperatures. Supporting 
evidence of this hypothesis comes from the attempted coupling of two mono TFA 
diamines in the presence of 1, 1-dicarbonyl imidazole. This reaction did not lead 
to the coupled urea product. Instead, a cyclic imidazoline compound formed 
(Scheme 3.7).  
 
 
 
 
 
            Scheme 3.7. Attempeted coupling of two Mono-TFA diamines 
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Figure 3.3. Formation of Cyclic Mono-TFA intermediate. 
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Out of curiosity, mono-TFA amine, 6, was heated in DMF at 50 oC, without 1, 1-
carbonyl diimidazole present resulting in the same product being formed. This 
suggests an intermolecular cyclization between the amino group and the 
carbonyl forming the initial hydrate. Water is eventually expelled to form the 5-
membered imidazolidine product (Fig. 3.4b).  
 
 
 
 
 
 
 
 
 
                         
 
 
 
 
  
 
                      Figure 3.4b. X-ray crystal structure of compound 6b. 
 
Another hypothesis to explain mono-protection occurs is due to the ability of the 
trifluoroacetyl group (when it is attached to the diamine) to withdraw electrons 
from an unprotected amino group, not allowing that amino group to be reactive 
enough to attack a different ethyl trifluoroacetate molecule. At this point, mono-
TFA DPDA was synthesized in quantitative yield, but another mono-protected 
DPDA must be obtained, with its protecting group orthogonal to TFA. Earlier it 
was mentioned that attempting to mono-Boc DPDA lead to disastrous results, it 
was imagined that trying to mono-protect DPDA with other protecting groups 
would give the same outcome. However, an indirect method of making other 
mono-protected diamines can occur. We can use the mono-protected TFA 
molecule itself as a type of “intermediate” by protection of the free amine and 
then subsequent removal of the TFA protecting group87 eventually leading to the 
desired mono-protected diamine.  
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           Scheme 3.8.  Synthesis of the orthogonally protected monomer.  
 
The BOC group seemed to be an ideal group due to it being orthogonal to a TFA 
group when it comes to deprotection. Treatment of the mono-protected-TFA 
diamine with Boc anhydride in acetonitrile, led to quantitative yield of the mixed 
orthogonally protected diamine, referred to as the “doubly protected monomer” 
(Scheme 3.8). In order to obtain the mono-Boc diamine, the TFA protecting 
group needed to be removed. Such groups can be removed by reaction with a 
hydroxide base, such as LiOH or by using NaBH4. Attempted removal of the 
protecting group with NaBH4 (refluxing in MeOH) was not successful. Another 
approach to remove the TFA   protecting group87 utilized an excess of LiOH in 
MeOH (Scheme 3.9). However, this reaction does not go to completion and it is 
not known why this reaction does so. The product was easily separated by 
column chromatography and the recovered starting material was resubmitted to 
the same reaction conditions. This was repeated until all of the starting material 
was consumed. Therefore, it is possible to generate the mono-Boc diamine 
indirectly though this method in high yields, rather than a direct synthesis of the 
mono-Boc diamine.  
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                             Scheme 3.9. Synthesis of Mono-BOC DPDA 
 
3.3 Diamine Mono Activation Strategies and Diamine Coupling Reactions 
In order to form a urea-linked dimer one of the carbonyl units must be activated 
towards coupling. The literature shows a few ways to accomplish this activation. 
Some of these methods include: formation of an isocyanate via triphosgene88,89 
(Scheme 3.10); reaction with 1, 1-dicarbonyl imidazole90  (Scheme 3.11) leading  
 
 
 
 
 
 
 
 
 
 
 
                            Scheme 3.10. Triphosgene Methodology. 
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to a reactive intermediate and the synthesis of a stable isocyanate precursor 
from  p-nitrophenyl  chloroformate  (Scheme 3.12).91 The problems with al l  
th   
 
 
 
 
 
 
                          Scheme 3.11. Carbonyl imidazole methodology 
 
the previously mentioned methods include handling of very reactive materials, 
use of anhydrous solvents (in the case of dicarbonyl imidazole) and not being 
able to control the reaction. Despite these drawbacks, the route utilizing 
p−nitrochloroformate92 had distinct advantages over the other methods. One 
major advantage is the ease of purification of p-nitrophenyl carbamates, which  
tends  t0  
 
 
 
 
 
 
 
 
 
 
    Scheme 3.12. Synthesis of p−nitrophenyl DPDA carbamate precursor 
 
tends to form crystalline compounds. The literature shows that these types of 
compounds decompose over a time period of several months. At this point a 
crossroad was reached in the synthesis. Both the carbamates from the mono-
Boc diamine and the TFA diamine could be made. Previous work from another 
project showed that reaction of 2 equivalents of the mono-TFA p-nitrophenyl 
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carbamate with DPDA led to both the desired product and also the transfer of the 
TFA group to another DPDA molecule. Use of the mono-Boc p-nitrophenyl 
carbamate did not lead to the transfer of the Boc group from on diamine to 
another (Scheme 3.12). This led to the decision of use the mono-Boc DPDA 
carbamate as the coupling molecule. It is thought that the electron withdrawing p-
nitrophenoxy moiety is responsible for this type of the transfer of the 
trifluoroacetyl group to a free amine.  Earlier, it was mentioned that these types of 
molecules decompose over time. One very simple experiment to determine how 
long it would before the molecule, 10, decomposed, was just to let it sit in solvent 
(this case CHCl3) over a one week period. Three days later white needles began 
to form. It was determined the structure was, 10b, by NMR. 
 
                                       
 
 
 
                Figure 3.5. An intermolecular cyclization product. 
 
The p nitrophenyl carbamate decomposed, presumably forming the isocyanate in 
situ, which was subsequentially attacked by the BOC carbamate nitrogen. 
Therefore, reaction of a mono-BOC DPDA p-nitrophenyl carbamate with another 
mono-TFA protected DPDA molecule, 6 & 26, in DMF lead to the orthogonally 
protected dimer, 11 & 29 , in good yields (Scheme 3.13).Now that the orthogonal 
protected dimer, 11 & 29, was in hand, the next step was the attachment of 
specific amino acid residues to the molecule. First, the dimer had to be 
deprotected and once again LiOH was used to carry out this task. Deprotection 
of the dimer was accomplished using excess LiOH in MeOH (Scheme 3.14). 
This reaction was also observed to reach equilibrium. The starting material was 
separated from the deprotected TFA product and the starting material was 
subjected to the same reaction conditions.  
 
O
NH
10b
N
O
O
 48
 
 
 
 
 
 
 
 
 
 
 
 
                         Scheme 3.13. Synthesis of orthogonal protected dimer. 
 
 
 
 
 
 
 
 
 
 
 
                                  Scheme 3.14. TFA deprotection of dimer. 
 
3.4 Activated Amino Acid Techniques and “Trimer” Synthesis 
In order to introduce both diversity, as well as functionality into the 
peptidomimetic, two amino acids Lysine and Alanine, were chosen. Lysine allows 
the peptidomimetic to have the positive charge necessary for attraction to 
bacterial membranes and alanine was needed to act as a spacer and to provide 
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variability to our mimic. At this stage both amino acids (lysine and alanine) 
needed to be converted to their activated forms93 (p-nitrophenyl carbamates) for 
coupling (Scheme 3.15). Unfortunately, both amino acids needed to be protected 
as their methyl ester. If the carboxylic acid end of the amino acid is not protected 
as an ester, the molecule could close upon itself forming a cyclized product. The 
methyl esters of both amino acids (lysine also had its ε−amino group protected 
as 
 
 
 
 
 
 
 
 
                     Scheme 3.15.  Amino acid activation. 
 
as a BOC carbamate) were reacted (individually) with p-nitrophenyl 
chloroformate affording the p-nitrophenyl carbamate of both amino acids esters 
in moderate yield (Scheme 3.15). In the next step, these amino acid carbamates 
were reacted with the mono-protected dimer, respectively, to afford what we refer 
to as a Boc-protected "trimer" in moderate yields (Scheme 3.16 - for Lys) 
(Scheme 3.17 - for Ala). 
 
 
 
 
 
 
 
                   Figure 3.6. Cyclized product from activated amino acid.         
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3.5 Protecting group modifications  
 
 
 
 
 
 
 
 
                     Scheme 3.16.  Synthesis of protected lysine “trimers”. 
 
 
 
 
 
 
 
 
 
                    Scheme 3.17.  Synthesis of protected alanine “trimers”. 
 
3.5 Protecting group modifications  
Using the Boc protecting group allowed easy access to the trimeric units. 
However, it was found later that BOC protecting groups are not compatible with 
the  solid  phase  resin (Knorr) that was used in this study. In order to prepare the  
molecule for solid phase synthesis it was decided to replace the BOC protecting 
group with a Teoc (Trimethylsilylethyl) group. Amines can be protected as a Teoc 
carbamate by their reaction with Teoc carbonate.17 Teoc carbonate was prepared 
by reaction of trimethylsilyl ethanol with one equivalent of p-nitrophenyl 
chloroformate affording Teoc carbonate in good yield (Scheme 3.18). 
                           Scheme 3.18.  Synthesis of Teoc carbonate. 
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group with a Teoc (Trimethylsilylethyl) group. Amines can be protected as a Teoc 
carbamate by their reaction with Teoc carbonate.94 Teoc carbonate was prepared 
by reaction of trimethylsilyl ethanol with one equivalent of p-nitrophenyl 
chloroformate affording Teoc carbonate in good yield (Scheme 3.18).  
 
 
 
 
 
 
 
 
 
 
                Scheme 3.19.  Synthesis of Teoc protected lysine “trimers”. 
 
 
 
 
 
 
 
 
 
 
 
              Scheme 3.20.  Synthesis of Teoc protected alanine “trimers”. 
 
Teoc carbonate, 47, was reacted with the Boc deprotected (by trifluoroacetic 
acid) trimer, effectively switching the terminal protection group (Scheme 3.19 
and Scheme 3.20). The obvious question here should be why Teoc protecting 
group strategy was not used from the very beginning of the synthesis. After 
asking ourselves this same question, a reaction of Teoc carbamate and the 
mono-TFA DPDA was attempted. This reaction lead to several different 
compounds being formed and the abandonment of this approach. To synthesize 
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the alanine trimeric precursor, 22 & 40, the methyl ester was carefully saponified 
with ice cold 1M LiOH to avoid racemization (Scheme 3.21).   
 
 
 
 
 
 
 
 
 
                 Scheme 3.21.  Saponification of Alanine methyl ester. 
 
For the ε−Z protected lysine trimer precursor more protecting group strategies 
had to be utilized. Therefore, the Z group was removed in via hydrogenolysis in 
the presence of BOC anhydride to directly convert the newly formed free amine 
to a tert-butyloxy carbamate (Scheme 3.22). The final reaction was the careful 
hydrolysis of the protected lysine methyl ester with ice-cold 1M LiOH in methanol 
and with acidic workup of this basic mixture (Scheme 3.23) the carboxylic acid 
was formed in good yield. 
 
 
 
 
 
 
 
 
 
 
                  Scheme 3.22.  Hydrogenation of Teoc protected “Trimer”. 
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      Scheme 3.23.  Saponification of Teoc protected “Trimer”. 
3.6 Solid Phase Synthesis 
The preceding reactions were used to 
generate the oligoureas (trimers), that are 
needed for fragment condensation on the 
solid phase.95 One of the problems with 
solid phase synthesis is the costs of the 
solid phase resins themselves, with the 
Wang resin being the most cost effective. 
Since many different types of reactions   
can now be done on the solid support,        Figure 3.7. Knorr’s linkerqq                     
including organometallic reactions, having a variety of different resins is 
important, because some reactions will only work on specific resins (due to their 
swelling capacity and solvent compatibility). In our situation, we used a 
polystyrene resin with Knorr’s linker (Fig. 3.7), which is commonly referred to as 
Knorr’s resin and is one of the traditional solid phase synthesis resins used in the 
synthesis of peptides.96  The linker, protected by an Fmoc group, must be 
removed by washing 3 times with a piperidine/DMF solution, resulting in 
deprotection and the formation of a fulvene (Scheme 3.24). After deprotection 
was completed; the resin was checked using the Kaiser test. The Kaiser test is a 
very sensitive colorimetric test, developed by Kaiser in the 70’s to determine the 
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presence of a primary 
amine.97 After After 
After detection of the 
free amine an attempt 
was made to couple 
an oligourea trimer to 
   Scheme  3.24.  Deprotection of FMOC amine. Aa Knorr’s resin. aaaaaa   
Unfortunately, carboxylic acids do not react directly with amines. Therefore, 
carboxylic acids must be converted to an activated ester prior to use. There are 
many different approaches for making activated esters.98 The goal of all of these 
different methods is to quickly make an activated ester and suppress any 
possible amino acid racemization. In our case, we decided to use Castro’s 
Reagent (BOP) as the activating agent with HOBt to suppress any possible 
racemization.  
 
 
 
 
 
 
 
 
                        Scheme 3.25.  First step in making an activated ester. 
 
The first step in this process is the deprotonation of the carboxylic acid with 
Hunig’s Base (DIPEA), (Scheme 3.25) then esterification with Castro’s reagent 
in the presence of hydroxybenzotriazole (HOBt) (which suppresses racemization) 
(Scheme 3.26). After the activated ester was formed, the mixture was added to 
the reaction vessel containing the deprotected solid phase resin and was allowed 
to react for several days at room temperature. The resin was tested under Kaiser 
conditions to determine if any free amine groups were present.  
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                  Scheme 3.26.  Second step in making an activated ester. 
The Kaiser test was positive, indicating the presence of a free amine. This shows 
that no coupling reactions had taken place; only starting material (activated ester) 
was recovered. This reaction was attempted several more times, only to end up 
unsuccessful. Other attempts were made, at slightly elevated temperatures. No 
coupling of the solid phase precursor to the resin occurred in this case as well. 
Two other oligourea trimers (the R,R diastereomer, 34 and the alanine containing 
oligourea 22) were also tested as well. In these cases, no coupling occurred as 
well. One possible reason why coupling was not occurring could be caused by 
the actual solid phase resin itself. It could be that the Knorr resin is incompatible 
for this type of synthesis. Unfortunately, no other resins were used and there was 
not enough material to be used in future reactions at the time of this writing. 
Another possible reason why coupling did not occur could be related to the size 
of the solid phase precursors. There could be possible steric interactions 
influencing the approach of the activated ester to the resin, allowing a reaction 
not to occur. In order to continue this project, the problems associated with the 
solid phase must be corrected. Another student will carry on this project at this 
point. Next, the syntheses to the precursors used in this work will be described in 
the next section. 
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3.7 Experimental Procedure 
N N
3  
2, 2-Spirocyclohexane-4, 5-diphenyl-2H-imidazole84 
A 2-L, three-necked, round-bottomed flask equipped with a mechanical stirrer 
and a reflux condenser is charged with 1.0 L of glacial acetic acid, 158 g (0.75 
mol) of benzil, 400 g of ammonium acetate and 80 mL (0.77 mol) of 
cyclohexanone. The mixture is stirred and heated at reflux temperature for 1.5 hr 
and then, while hot, poured into 3 L of vigorously stirred water. The mixture is left 
overnight to cool to ambient temperature and crystals are collected by filtration, 
washed 4 times with 300 mL of water, crushed in a mortar and dried under 
reduced pressure to give 207 g (96 %) of the product as beige crystals, mp 105 – 
106 °C; 1H NMR (Varian 400 MHz; (DMSO−d6)  δ: 1.65 – 1.92 (m, 6H), 1.95 – 
2.00 (m, 4H), 7.33 – 7.53 (m, 10H); 13C NMR (Varian 400 MHz; (DMSO−d6)  δ: 
24.1, 25.7, 34.7, 104.1, 128.3, 128.9, 129.9, 133.1, and 164.0.  
 
NH2
4
NH2
 
 
(±)−1, 2−Diphenyl−1, 2−ethylenediamine84 
 A 2 L, four-necked, round-bottomed flask equipped with a mechanical stirrer, 
thermometer and dry ice condenser is charged with 72.0 g (0.250 mol) of 
2,2−spirocyclohexane−4,5−diphenyl−2H−imidazole, 3. The flask is flushed with 
argon, and 400 mL of THF is added. The mixture is stirred until all solids 
dissolve, cooled to −78 °C (dry ice/acetone bath) and treated with a stream of 
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gaseous NH3 until the volume of liquid increases by about 400 mL. One of the 
side necks is then equipped with a solids addition funnel and 6.94 g (1.00 mol) of 
lithium is slowly introduced by cutting the wire with scissors in a gentle stream of 
argon. The rate of lithium addition is such that the temperature does not rise 
above − 65 °C. Following the addition of lithium, the mixture is stirred for 30 min 
and 30 mL (1.0 mol) of ethanol is slowly added. The mixture is stirred for an 
additional 20 min and 70.0 g of NH4Cl is added. The cooling bath is removed, the 
mixture is allowed to warm to 0 °C, 400 mL of water is carefully introduced, and 
the phases are separated. The aqueous phase is washed 3 times with 300 mL of 
ether and the combined organic extracts are washed with brine, dried over 
anhydrous sodium sulfate, filtered and concentrated with a rotary evaporator to 
about 200 mL. The solution is transferred to a 1 L, one-necked, round-bottomed 
flask equipped with a mechanical stirrer, cooled to 0 °C and treated with 300 mL 
of 2 N aqueous HCl. The biphasic mixture is vigorously stirred at ambient 
temperature for 1 hr, 500 mL of water is added and phases are separated. The 
organic phase is washed with 150 mL of water and the combined aqueous 
phases are extracted with 300 mL of DCM. The aqueous solution is then 
carefully treated with 300 mL of 2 M NaOH and the mixture is extracted 4 times 
with 150 mL of DCM. The combined organic extracts are washed with brine, 
dried over anhydrous NaSO4, and filtered. Removal of volatile material under 
reduced pressure (water aspirator) gives 48.0 g (92.1 % yield) of racemic 
diamine as a pale yellow solid, mp 81 – 82 °C, lit.84 mp 82 °C; 1H NMR (Varian 
400 MHz; (DMSO−d6)  δ: 1.90 (s, 4H), 3.82 (s, 2H), 7.06 – 7.17 (m, 10H); 13C 
NMR (Varian 400 MHz; (DMSO−d6) δ: 61.9, 126.8, 126.9, 128.2, and 143.4.  
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(1S, 2S)− (−) −and (1R, 2R)− (+)−1, 2−Diphenyl−1, 2−ethylenediamine84 
“S,S and R,R Parent Diamine” 
 A 1 L, round-bottomed flask equipped with a mechanical stirrer is charged with 
42.5 g (0.20 mol) of the racemic diamine, 4, and 230 mL of ethanol. The solids 
are dissolved by heating the mixture to 70 °C whereupon a hot (70 °C), 
homogeneous solution, of 30.0 g (0.200 mol) of L−(+)−tartaric acid in 230 mL of 
ethanol is added. The tartrate salts precipitate immediately, and after the mixture 
is cooled to ambient temperature, the crystals are collected by filtration, washed 
twice with 60 mL of ethanol, and dried under reduced pressure. The solids are 
dissolved in 230 mL of boiling water, 230 mL of ethanol is added and the 
homogeneous solution is allowed to cool slowly to room temperature. The 
crystals are collected by filtration, washed with 40 mL of ethanol and dried under 
reduced pressure. The recrystallization procedure is then repeated twice using 
the same volumes of solvents (230 mL of water and 230 mL of ethanol) to give 
23 – 25 g (63 – 69%) of the tartrate salt as colorless crystals, [α]23D −10.8 ± 0.2° 
(H2O, c 1.3). The salt is transferred to a 1 L, one-necked, round-bottomed flask 
equipped with a magnetic stirring bar and suspended in 300 mL of water. After 
the mixture is vigorously stirred and then cooled to 0 – 5°C, 23 mL of 50 % 
aqueous NaOH is added dropwise followed by 150 mL of DCM and stirring is 
continued for 30 min. The phases are separated, the aqueous phase is washed 
twice with 50 mL of DCM and the combined organic extracts are washed with 
brine, dried over anhydrous NaSO4 and filtered. Removal of the volatile material 
under reduced pressure gives a colorless solid that is recrystallized from hexane 
to yield 12 – 14 g (57–66%) of (S,S)−(−)−diamine as colorless crystals, [α]23D 
−106 ± 1° (MeOH, c 1.1) lit.84 [α]23D −106.5 ° (MeOH, c 1.09). The filtrates from 
all crystallizations are combined and the solvent is evaporated on a rotary 
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evaporator under vacuum (water aspirator). The residual solid is transferred to a 
1 L, one-necked, round-bottomed flask equipped with a magnetic stirring bar, and 
suspended in 250 mL of water. To this vigorously stirred mixture is slowly added 
25 mL of aqueous 50 % NaOH followed by 200 mL of DCM and the stirring is 
continued for 30 min. The phases are separated, the aqueous phase is washed 
twice with 50 mL of DCM and the combined organic extracts are washed with 
brine, dried over anhydrous NaSO4 and filtered. Removal of volatile material 
under reduced pressure gives 24 – 27 g of the enriched (R,R)−diamine as pale 
yellow crystals. This material is treated with D−(−)−tartaric acid and the resulting 
salt is recrystallized in exactly the same manner as described for the other 
enantiomer to give 29 – 31 g (80 – 85%) of colorless crystals, [α]23 D +4 ± 0.5 ° 
(H2O, c 1.3). Treatment with NaOH, as described above, followed by 
crystallization from hexane gives 11.5 – 13 g (54 – 61%) of (R,R)−(+)−diamine as 
colorless crystals, [α]23 D +106 ± 1° (MeOH, c 1.1); 1H NMR (Varian 400 MHz; 
(DMSO−d6) δ: 1.65 – 1.92 (m, 6H), 1.95 – 2.00 (m, 4H), 7.33 – 7.53 (m, 10H). 
13C NMR (Varian 400 MHz; (DMSO−d6) δ: 24.1, 25.7, 34.7, 104.1, 128.3, 128.9, 
129.9, 133.1, and 164.10. 
NH2
6
NH
O
F3C
 
N−(2−Amino−S,S−1,2−diphenylethyl)−2, 2,2,trifluoroacetamide86 
“S,S − Mono TFA Diamine” 
 
To a 250 mL round bottom flask was added 10.0 (32.5 mmol) of 
S,S−1,2−diphenyl−1,2−diamine in 100 mL of DCM. Next, the solution was cooled 
to 0 oC and a previously chilled solution of ethyl trifluoroacetate (5.00 mL, 35.0 
mmol) in 10 mL of DCM was added dropwise with stirring. After a while a gel 
formed and stirring was increased. After addition, the solution was allowed to stir 
for 1 hr at 0 oC. The solvent was removed carefully under rotary evaporation then 
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placed under vacuum for 24 hrs, allowing for a quantitative yield (14.5 g) of the S, 
S−Mono−TFA protected diamine. Melting pt. = 182-183 oC. 
1H NMR (Varian 400 MHz; (DMSO−d6) δ:  4.22 (d, 1H, J = 8.27 Hz); 4.92 (d, 1H, 
J = 8.27 Hz); 7.09 – 7.22 (m, 10H). 13C NMR (Varian 400 MHz; (DMSO−d6) δ:  
59.35, 61.06, 111.66, 114.53, 117.40, 120.27, 126.77, 127.08, 127.23, 127.57, 
127.80, 128.02, 139.88, 143.07, 155.43, 155.79, 156.15, and 156.51. 
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N−(2−Amino−R,R−1, 2−diphenylethyl)−2,2,2−trifluoroacetamide86 
“R, R−Mono TFA Diamine” 
 
To a 250 mL round bottom flask was added 9.00 (29.2 mmol) of 
R,R−1,2−diphenyl−1,2−diamine, 24, in 100 mL of DCM. Next, the solution was 
cooled to 0 oC and a previously chilled solution of ethyl trifluoroacetate (4.50 mL, 
31.7 mmol) in 10 mL of DCM was added dropwise with stirring. After a while a 
gel formed and stirring was increased. After addition, the solution was allowed to 
stir for 1 hr at 0 oC. The solvent was removed carefully under rotary evaporation, 
then placed under vacuum for 24 hrs, allowing for a quantitative yield (13.1 g) of 
the R,R−Mono−TFA protected diamine, 25.  1H NMR (Varian 400 MHz; 
(DMSO−d6) δ:  4.24 (d, 1H, J = 8.27 Hz); 4.95 (d, 1H, J = 8.27 Hz); 7.12 – 7.24 
(m, 10H). 13C NMR (Varian 400 MHz; (DMSO−d6) δ: 59.50, 61.32, 111.72, 
114.55, 117.42, 120.25, 126.78, 127.11, 127.26, 127.58, 127.84, 128.05, 139.92, 
143.12, 155.47, 155.81, 156.19, and 156.55. 
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[S,S−1, 2−Diphenyl−2−(2, 2, 2−trifluoroacetylamino)−ethyl]− 
carbamic acid tert−butyl ester 
“S,S−Mixed Monomer” 
 
To a round bottom flask containing 7.25 g (23.5 mmol) of the S,S−mono TFA 
amine, 6, was added 125 mL of MeCN, a stirring bar and 5.25 g (24.1 mmol) of 
Boc anhydride. The reaction was stirred at room temperature and after 30 min. a 
white precipitate began to form. The reaction was allowed to continue stirring 
overnight. The next day, the solution was filtered allowing the recovery of white 
solid material which was recrystallized from EtOAc affording white needle-like 
crystals, 7. Yield = 9.35 g; % yield = 97.4; mp: 223-4 °C; 1H NMR (Varian 400 
MHz; (DMSO−d6)) δ:  1.27 (s, 9H); 5.09 − 5.13 (dd, 1H); 5.26 − 5.30 (dd, 1H); 
7.12 − 7.29 (m, 10H); 7.66 − 7.69 (d, 1H); 9.79 − 9.81 (d, 1H). 13C NMR (Varian 
400 MHz; (DMSO−d6) δ: 28.117, 57.712, 58.008, 78.138, 111.75, 114.42, 
117.29, 121.30, 127.02, 127.20, 127.3, 127.95, 128.09, 138.65, 140.15, 155.06, 
155.24, 155.63, 155.98, 156.38. .Anal. Calc: C, 61.76; H, 5.68; N, 6.86; F, 
13.96; Found: C, 61.69; H, 5.53; N, 6.77; F, 13.98. 
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[R,R−1, 2−Diphenyl−2−(2, 2, 2−trifluoroacetylamino)−ethyl]− 
carbamic acid tert−butyl ester 
“R,R−Mixed Monomer” 
 
To a 250 mL round bottom flask containing 6.5 g (21.3 mmol) of the R,R−mono 
TFA amine was added 125 mL of MeCN, a stirring bar and 9.25 g (42.4 mmol) of 
BOC anhydride. The reaction was stirred at room temperature and after 30 min. 
a white precipitate began to form. The reaction was allowed to continue stirring 
overnight. The next day, the solution was filtered allowing the recovery of white 
solid material which was recrystallized from EtOAc affording white needle-like 
crystals. Yield = 8.12 g; Percent yield = 94.2 %. 1H NMR (Varian 400 MHz; 
(DMSO−d6) δ:  1.28 (s, 9H); 5.10 − 5.15 (dd, 1H); 5.28 − 5.32 (dd, 1H); 7.14 − 
7.31 (m, 10H); 7.68 − 7.72 (d, 1H); 9.81 − 9.83 (d, 1H). 13C NMR (Varian 400 
MHz; (DMSO−d6) δ: 28.12, 57.73, 58.02, 78.16, 111.79, 114.42, 117.29, 121.32, 
127.10, 127.20, 127.3, 127.95, 128.11, 138.65, 140.15, 155.10, 155.23, 155.63, 
155.94, 156.34. 
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(2−Amino−S,S−1, 2−diphenylethyl)−carbamic acid tert−butyl ester 
“S,S−Mono − BOC Diamine” 
 
8.00 g (19.6 mmol) of the S, S-mixed monomer was added to a 250 mL round 
bottom flask and was suspended in 100 mL MeOH. 1.50 g (32.65 mmol) LiOH 
was added and the solution was brought to reflux and allowed to reflux overnight. 
The next day the solution was allowed to cool to room temperature and the 
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MeOH removed via rotary evaporation. The product was suspended in water and 
extracted with EtOAc. This was repeated two more times and the organic 
extracts were combined and dried over anhydrous Na2SO4. The salts were 
removed and EtOAc removed by rotary evaporation. The compound was purified 
by column chromatography using first 100 % CHCl3 to remove any starting 
material and then with 100 % EtOAc to obtain the product as a pale yellow 
gummy solid. Unfortunately, this reaction reaches equilibrium and does not 
continue. This reaction was repeated with the remaining starting material until all 
the starting material was consumed and was worked up in the same manner 
(twice). Total yield for all combined reactions was 5.90 g  (96.4 %) 1H NMR 
(Varian 400 MHz (DMSO−d6) δ: 1.32 (s, 9H); 4.08 (d, 1H, J = 6.66 Hz); 4.70 (t, 
1H, J = 7.69 Hz, J = 7.80 Hz); 7.12 − 7.27 (m, 10H); 7.38 (d, 1H, J = 8.91 Hz). 
13C NMR (Varian 400 MHz; (DMSO−d6) δ: 28.23, 60.03, 61.20, 77.81, 126.47, 
126.54, 127.06, 127.23, 127.67, 127.78, 142.08, 143.30, 155.27. Anal. Calc: C, 
73.05; H, 7.74; N, 8.97. Found: C, 72.99; H, 8.53; N, 8.67.  
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(2−Amino−R,R−1, 2−diphenylethyl)−carbamic acid tert−butyl ester 
“R,R−Mono − BOC Diamine” 
 
7.00 g (17.1 mmol) of the R, R-mixed monomer was added to a 250 mL round 
bottom flask and was suspended in 100 mL MeOH. 1.50 g (33.7 mmol) LiOH was 
added and the solution was brought to reflux and allowed to reflux overnight. The 
next day the solution was allowed to cool to room temperature and the MeOH 
removed via rotary evaporation. The product was suspended in water and 
extracted with EtOAc. This was repeated two more times and the organic 
extracts were combined and dried over anhydrous Na2SO4. The salts were 
removed and EtOAc removed by rotary evaporation. The compound was purified 
by column chromatography using first 100 % CHCl3 to remove any starting 
 64
material and then with 100 % EtOAc to obtain the product as a pale yellow 
gummy solid. This reaction was repeated with the remaining starting material 
obtained from column chromatography until all the starting material was 
consumed and was worked up in the same manner. Total yield for all combined 
reactions was 94 % (5.02 g). 
 
10
NH
O
HN
O
O
OO2N
 
(2−tert−Butoxycarbonyl−1, 2−diphenylethyl)− 
carbamic acid. 4−Nitrophenyl Ester 
“S,S−Activated Boc Diamine” 
 
A 100 mL round bottom flask was charged with 3.50 g (17.4 mmol) of p-
nitrophenyl chloroformate in 50 mL THF. Next, the solution was cooled to 0 °C 
and a previously prepared solution containing 5.00 g of the mono-BOC diamine, 
8, 1.75 mL Et3N in 10 mL of THF. This solution was added dropwise with stirring 
into the flask containing the p−nitrophenyl chloroformate. After addition was 
complete, the solution was allowed to warm to room temperature for 2 hrs. After 
this two hour period elapsed, the solution was allowed to reflux for 1 hr. After the 
reflux period expired, the solvent was removed by rotary evaporation leaving 
behind an off-white colored residue. Water was added to dissolve the Et3N+ Cl− 
salts, then CHCl3 was added and the solution was shaken. The organic layer was 
dried over anhydrous Na2SO4. The salts were removed by filtration and the 
solvent removed by rotary evaporation affording 7.97 g of product. The 
compound was recrystallized from EtOAc affording 7.81 g (94.3%) of the 
monoactivated mono-Boc diamine. mp = 164 − 165 oC. 1H NMR (Varian 400 
MHz; (DMSO−d6) δ: 1.28 (s, 9H); 4.99 − 5.05 (m, 2H); 7.18 − 7.34 (m, 12H); 7.52 
− 7.54 (d, 1H J = 9.11 Hz); 8.19 − 8.23 (dt, 2H); 8.60 − 8.62 (d, 1H, J = 8.88 Hz). 
13C NMR (Varian 400 MHz; (DMSO−d6) δ: 28.8; 59.08; 60.32; 78.72; 122.74; 
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125.84; 127.69; 128.65; 140.53; 141.34; 144.75; 153.36; 155.69; 156.63. Anal. 
Calc: C, 65.40; H, 5.70; N, 8.80. Found: C, 65.42; H, 5.53; N, 8.77. 
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(2−tert−Butoxycarbonyl−1, 2−diphenylethyl)− 
carbamic acid. 4−Nitrophenyl Ester 
“R,R−Activated Boc Diamine” 
 
A 100 mL round bottom flask was charged with 3.00 g (14.9 mmol) of 
p−nitrophenyl chloroformate in 35 mL THF. Next, the solution was cooled to 0 °C 
and a previously prepared solution containing 4.50 g of the R,R−Mono−BOC 
diamine, 27, 1.50 mL Et3N in 10 mL of THF. This solution was added dropwise 
with stirring into the flask containing the p−nitrophenyl chloroformate. After 
addition was complete, the solution was allowed to warm to room temperature for 
2 hrs. After this two hour period elapsed, the solution was allowed to reflux for 1 
hr. After the reflux period expired, the solvent was removed by rotary evaporation 
leaving behind an off-white colored residue. Water was added to dissolve the 
Et3N+ Cl− salts, then CHCl3 was added and the solution was shaken. The organic 
layer was dried over anhydrous Na2SO4. The salts were removed by filtration and 
the solvent removed by rotary evaporation affording 6.54 g of product. The 
compound was recrystallized from EtOAc affording 6.23 g (87.6 %) of the 
monoactivated Mono−Boc diamine. mp = 164 − 165 oC. 
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“Orthogonally Protected S,S−TFA/BOC Dimer” 
To a round bottom flask containing 4.50 g (16.2 mmol) of the Mono−TFA 
compound, 6, in 10 mL of DMF was added a THF solution of the 
S,S−Μono−BOC activated compound, 10, was added dropwise with stirring. 
After addition was complete the solution was allowed to stir at room temperature 
overnight. The next day the solution was allowed to reflux for 1 hr. After the reflux 
period expired the solution was allowed to cool to room temperature and the 
DMF removed by high vacuum rotary evaporation. Next, the residue was 
dissolved in EtOAc and poured though a small pad of alumina (removes the 
nitrophenoxide anion). The product was chromatographed on silica eluting with 
50/50 EtOAc/Pet ether affording 9.25 g (88.3 %). 1H NMR (Varian 400 MHz; 
(DMSO−d6) δ:  1.28 (s, 9H); 4.74 − 4.79 (dd, 1H, J = 8.71 Hz, J = 8.71 Hz); 4.81 
− 4.91 (dd, 1H, J = 8.3 Hz, J = 8.3 Hz); 5.02 − 5.11 (m, 2H); 6.70 (d, 1H, J = 8.57 
Hz); 6.82 (d, 1H, J = 7.38 Hz); 7.02 − 7.14 (m, 20H); 7.39 (d, 1H, J = 9.12 Hz); 
10.1 (d, 1H, J = 7.55 Hz). 13C NMR (Varian 400 MHz; (DMSO−d6) δ: 28.18, 
28.29, 57.10, 57.58, 58.08, 58.48, 58.92, 59.23, 59.68, 77.98, 111.60, 114.47, 
117.34, 120.21,126.31, 126.49, 126.75, 126.83, 127.10, 127.19, 127.27, 127.39, 
127.52, 127.69, 127.79, 127.84, 127.90, 127.96, 128.10, 128.26, 138.87, 140.63, 
140.87, 141.59, 155.35, 155.43, 155.79, 156.15, 156.52, 157.36. Anal. Calc: C, 
66.86; H, 5.77; N, 8.66; F, 8.81. Found: C, 66.69; H, 5.65; N, 8.62; F, 8.76. 
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“Orthogonally Protected R,R−TFA/BOC Dimer” 
To a round bottom flask containing 3.50 g of the mono TFA compound, 25, in 10 
mL of DMF was added a THF solution of the R,R−mono−BOC activated 
compound, 28, was added dropwise with stirring. After addition was complete the 
solution was allowed to stir at room temperature overnight. The next day the 
solution was allowed to reflux for 1 hr. After the reflux period expired the solution 
was allowed to cool to room temperature and the DMF removed by high vacuum 
rotary evaporation. Next, the residue was dissolved in EtOAc and poured though 
a small pad of alumina (removes the nitrophenoxide). The product was 
chromatographed on silica eluting with 50/50 EtOAc/Pet ether affording 6.84 g of 
29. Percent yield = 92.1 % 
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“S,S−Mono−Boc Dimer” 
In a 100 ml round bottom flask was added 8.00 g (12.4 mmol) of the 
S,S−orthogonally protected dimer, 14, in 30 mL methanol. 1.50 g (33.7 mmol) 
LiOH was added and the solution was brought to reflux and allowed to reflux 
overnight. The next day the solution was allowed to cool to room temperature 
and the MeOH removed via rotary evaporation. The product was suspended in 
water and extracted three times with 25 mL EtOAc. The organic extracts were 
combined and dried over anhydrous Na2SO4. The salts were removed and 
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EtOAc removed by rotary evaporation. The product was purified by column 
chromatography first using 50/50 CHCl3/EtOAc to remove the starting material 
and then with 100 % EtOAc. The solvent was removed leaving behind a colorless 
oil. This reaction was repeated with the remaining starting material obtained from 
column chromatography until all the starting material was consumed and was 
worked up in the same manner. The total yield for all combined reactions is 90 % 
(6.15 g). 1H NMR (Varian 400 MHz; (DMSO−d6)  δ: 1.28 (s, 9H); 4.14 (d, 1H, J = 
3 .79 Hz); 4.63 (dd, 1H, J = 4.3 Hz, J = 8.2 Hz); 4.74 − 4.83 (m, 2H); 6.48 (d, 1H, 
J = 8.0 Hz); 7.04 (d, 1H, J = 7.3 Hz); 7.15 − 7.26 (m, 20H); 7.31 (d, 1H, J = 7.1 
Hz). 13C NMR (Varian 400 MHz; (DMSO−d6) δ: 28.16; 57.82; 59.09; 59.40; 
59.65; 77.95; 126.38, 126.48; 126.58; 126.61; 126.95; 127.10; 127.17; 127.65; 
127.71; 127.84; 141.13; 141.50; 142.65; 143.56; 155.06; 156.95. Anal. Calc: C, 
74.15; H, 6.96; N, 10.17. Found: C, 74.12; H, 6.89; N, 10.03.  
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“R,R−Mono−Boc Dimer” 
In a 100 mL round bottom flask was added 6.00 g (9.27 mmol) of the 
R,R−orthogonally protected dimer, 29, in 25 mL methanol. 1.50 g (33.7 mmol) 
LiOH was added and the solution was brought to reflux and allowed to reflux 
overnight. The next day the solution was allowed to cool to room temperature 
and the MeOH removed via rotary evaporation. The product was suspended in 
water and extracted three times with 25 mL EtOAc. The organic extracts were 
combined and dried over anhydrous Na2SO4. The salts were removed and 
EtOAc removed by rotary evaporation. The product was purified by column 
chromatography first using 50/50 CHCl3/EtOAc to remove the starting material 
and then with 100 % EtOAc. The solvent was removed leaving behind colorless 
oil. This reaction was repeated with the remaining starting material obtained from 
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column chromatography until all the starting material was consumed and was 
worked up in the same manner. Total yield for all combined reactions is 94 % 
(6.41 g).  
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ε−Cbz −(S)−Lysine α−PNP Carbamate Methyl Ester 
In a 250 mL round bottom flask was added 15.0 g of ε−Cbz−(S)−Lysine Methyl 
Ester, hydrochloride salt suspended in 50 mL THF. Next, 10 mL of TEA in 20 mL 
THF was added dropwise at room temperature. After addition was complete, the 
solution was allowed to stir for 1 hr. A white precipitate, the hydrochloride salt of 
TEA, precipitated out of solution. The white precipitate was filtered off and 5 mL 
of TEA was added to the remaining solution. Next, this solution was added 
dropwise into a different 250 mL round bottom containing 9.50 g (47.1 mmol) of 
pnitrophenyl chloroformate dissolved in 50 mL of THF. After addition was 
complete the solution was allowed to stir overnight. The next day a white 
precipitate that formed during the reaction was removed by filtration and the 
solvent was removed by evaporation, leaving behind a gummy residue. Hot ether 
was added and the mixture was triturated and then allowed to cool in a freezer. 
The product crystallized and was filtered giving a yield of 21.2 g (98.2 %). 1H 
NMR (Varian 400 MHz; (DMSO−d6) δ: 1.33 − 1.46 (m, 4H); 1.62 − 1.79 (m, 2H); 
2.99 (q, 2H, J = 6.2 Hz); 3.66 (s, 3H); 4.05 − 4.10 (m, 1H); 4.99 (s, 2H); 7.25 − 
7.35 (m, 5H); 7.38 − 7.41 (m, 2H); 8.24 − 8.28 (m, 2H); 8.53 (d, 1H, J = 7.6 Hz). 
13C NMR (Varian 400 MHz; (DMSO−d6) δ: 22.74, 28.94, 30.27, 52.07, 54.14, 
65.17, 122.37, 125.25, 127.75, 128.36, 137.30, 144.27, 153.31, 155.96, 156.15, 
172.35. Anal. Calc: C, 57.51; H, 5.48; N, 9.15; Found: C, 57.00; H, 5.53; N, 
9.03.  
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Alanine α−PNP Carbamate Methyl Ester 
5.0 g (35.8 mmol) of (S)−Alanine Methyl Ester, Hydrochloride salt and 7.50 g 
(37.2 mmol) of p nitrophenyl chloroformate were suspended in 100 mL DCM. 
Next, 3.50 mL of TEA mixed in 10 mL DCM was added dropwise at room 
temperature. After addition was complete, the solution was allowed to stir 
overnight. The next day, the mixture was washed with 25 mL of a saturated 
NaHCO3 solution and dried over anhydrous Na2SO4. The salts were removed by 
filtration and the amount of solvent was reduced to 15 mL. The solution was 
chromatographed over Silica, eluting with DCM (Rf = 0.25). The solvent was 
removed affording 7.23 g (75.3 %) of a pale yellow-green compound. 1H NMR 
(Varian 400 MHz; (DMSO−d6) δ:  1.35 (d, 3H, J = 7.3 Hz); 3.67 (s, 3H); 4.19 (dt, 
1H, J = 7.31 Hz, J = 7.32 Hz); 7.37 − 7.41 (m, 2H); 8.24 − 8.28 (m, 2H); 8.57 (d, 
1H, J = 7.3 Hz). 13C NMR (Varian 400 MHz; (DMSO−d6) δ: 16.80, 52.13, 49.54, 
122.38, 125.24, 144.27, 152.95, 155.93, 172.75.  
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2−(Trimethylsilyl) ethanol17 
A solution of 40 g of ethyl 2−(trimethylsilyl) acetate (0.25 mol) in 50 ml THF was 
cooled to −10 °C. Over a 2 hour period, 0.30 L of 1.02 M BH3·THF complex (0.30 
mol) was added through the septum with the aid of slight nitrogen pressure. The 
colorless solution was allowed to warm to room temperature and was left for 2 
days. The contents of the reaction vessel were transferred to a flask containing 
0.75 L of MeOH. After being stirred for 20 hours under nitrogen, the solution was 
concentrated at 25 − 28 °C until only 140 mL remained. This was distilled under 
vacuum through a Vigreux column affording 25.0 g of the alcohol, 46. 
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Teoc Carbonate17 
In a 250 mL round bottom flask were added 20.0 g of p− nitrophenyl 
chloroformate (99.2 mmol) and 11.0 g of 2−(trimethylsilyl) ethanol in 150 mL of 
DCM. A solution of 9.5 mL of TEA and 20 mL of DCM was added dropwise into 
the solution containing the silyl compound. After addition, the solution was 
allowed to stir overnight at room temperature. The next day the solution was 
extracted with 0.5 M HCl and the organic layer was neutralized with NaHCO3. 
The organic layer was dried over anhydrous Na2SO4. Trituration of this residue 
with hexane yielded a white precipitate (p− nitrophenyl carbonate). Evaporation 
of the hexane solution, after filtration of the solid left behind an oil, which was 
stirred with 250 mL of ice-cold water containing 5 drops of formic acid. The white 
precipitate that formed was filtered and dried overnight affording 21.1 g (79.6 %) 
of 2−(Trimethylsilyl)−ethyl−4−nitrophenyl carbonate, 47. 
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S,S−Cbz−Boc−Lys−Trimer 
In a 100 mL round bottom flask charged with 25 mL DMF was added 5.50 g (6.31 
mmol) of ε−Cbz−(S)−Lysine α−PNP Carbamate Methyl Ester, 41, along with 5.00 
g (10.9 mmol) of Mono−Boc dimer, 12. A solution of TEA in 5 mL DMF was 
added dropwise into the previously mentioned flask. After addition was complete, 
the solution was warmed to 50 °C with stirring for a 24 hr period. After the period 
elapsed, DMF was removed via high vacuum rotary evaporation. The residue 
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was suspended in EtOAc and passed through a short pad of Alumina, which 
traps the p-nitrophenoxide ion.  EtOAc was reduced to 10 mL and the mixture 
was chromatographed over silica eluting with a 60:40 mixture of EtOAc/hexanes. 
Rf = 0.22 The organic portions were combined; the solvents removed affording 
4.93 g (89.8 %) of the fully protected trimer, 13. 1H NMR (Varian 400 MHz; 
(DMSO−d6) δ: 1.13 − 1.20 (m, 2H); 1.23 (s, 9H); 1.29 − 1.36 (m, 2H); 1.44 − 1.60 
(m, 2H); 2.90 (dd, 1H; J = 6.7 Hz, J = 12. 9 Hz); 3.60 (s, 3H); 4.09 (dd, 1H, J = 
7.7 Hz, J = 13.3 Hz); 4.74 (t, 1H, J = 8.3 Hz); 4.80 − 4.82 (m, 2H); 4.88 (t, 1H, J = 
8.1 Hz); 4.97 (s, 2H); 6.39 − 6.41 (d, 1H, J = 7.76 Hz); 6.57 (d, 1H, J = 7.5 Hz); 
6.78 (d, 1H, J = 8.8 Hz); 6.89 − 6.91 (m, 4H); 7.10 − 7.37 (m, 25H). 13C NMR 
(Varian 400 MHz; (DMSO−d6) δ: 22.34, 28.14, 29.01, 31.65, 51.70, 52.41, 57.93, 
58.00, 58.32, 59.45, 65.10, 77.67, 126.60, 126.77, 127.19, 127.25, 127.41, 
127.47, 127.61, 127.72, 127.76, 128.35, 137.27, 140.48, 141.06, 141.44, 155.06, 
156.05, 156.95, 157.19, 173.57. MALDI−TOF−MS: m/z 771 [M-Boc], 
772[M+H−Boc], 793 [M+H−Boc], 871 [M+], 872 [M+H],     893 [M+Na],  894 
[M+H+Na],  909 [M+K],  910 [M+H+K]. Anal. Calc: C, 68.95; H, 6.71; N, 9.65. 
Found: C, 68.69; H, 6.53; N, 9.60. 
 
HN
NH
Ph
Ph
O
N
H
Ph
PhNHHN
O
O
O
H3C
(CH2)4HNO
Bn
O
O
O
SiMe3
14
 
Teoc−S,S−Cbz−Lys−Trimer 
The previously synthesized S,S−Cbz−Lys−Trimer, 13, in the amount of 4.00 g 
(4.59 mmol) was submitted to deprotection conditions using 3 eq. of TFA in 10 
mL DCM for a 24 hr period. Afterwards, excess TFA and DCM were removed by 
rotary evaporation leaving behind a syrupy residue. This residue was dissolved 
10 mL of DCM and washed 5 times with saturated NaHCO3 solution. The organic 
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layer was saved and dried over anhydrous NaSO4. The salts were filtered and 
DCM removed. Next, 10 mL of DMF were added along with 3 eq. of Teoc 
Carbonate, 47 and allowed to stir at room temperature for 24 hrs. The next day, 
DMF was removed via high vacuum rotary evaporation. The resulting residue 
was taken up in EtOAc and chromatographed over alumina, eluting with 50/50 
EtOAc/hexane. The solvents were removed affording 4.05 g of 
Teoc−S,S−Cbz−Lys-Trimer, 14, with a yield of 96.5 %. 1H NMR (Varian 400 MHz; 
(DMSO−d6) δ: −0.05 (s, 9H); 0.78 − 0.82 (m, 2H), 1.19 − 1.24 (m, 2H); 1.34 
− 1.41 (m, 2H); 1.45 − 1.60 (m, 2H), 2.94 − 2.99 (q, 2H, J = 6.67 Hz, J = 13.04 
Hz); 3.53 (s, 3H); 3.87 − 3.91 (t, 2H, J = 7.92 Hz); 4.04 − 4.09 (q, 1H, J = 7.47 
Hz, J = 13.67 Hz); 4.72 − 4.76 (t, 1H, J = 8.48 Hz); 4.81 − 4.83 (m, 2H); 4.84 
− 4.89 ( t, 1H, J = 8.28 Hz); 5.00 (s, 2H); 6.37 − 6.39 (d, 1H, J = 7.96 Hz); 6.41 
− 6.43 (d, 1H, J = 7.80 Hz); 6.53  −  6.55 (d, 1H, J = 7.50 Hz); 6.80 −  6.82 (d, 1H, 
J = 8.26 Hz); 6.92 − 6.94 (m, 2H); 7.05 − 7.38 (m, 25H); 7.55 − 7.57 (d, 1H, J = 
8.87 Hz). 13C NMR (Varian 400 MHz; (DMSO-d6) δ: −1.46, 17.28, 22.31, 28.29, 
29.19, 31.61, 51,59, 52.28, 52.55, 57.82, 57.99, 58.37, 58.45, 61.61, 77.41, 
126.64, 126.65, 127.13, 127.22, 127.25, 127.38, 127.48, 127.60, 127.66, 127.76, 
127.88, 139.92, 140.55, 141.03, 141.42, 155.58, 157.12, 157.69, 159.22, 173.56. 
MALDI−TOF−MS: m/z  915 [M+], 916 [M+H], 937 [M+Na], 938 [M+H+K]. Anal. 
Calc: C, 66.93; H, 6.83; N, 9.18; Si, 3.07. Found: C, 66.69; H, 6.83; N, 9.20; Si, 
2.96. 
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Teoc−S,S−Boc−Lys−Trimer 
In a small hydrogenation flask were added, 3.00 g (3.28 mmol) of the 
Teoc−S,S−Cbz−Lys−Trimer, 14, 10 mL of anhydrous MeOH, 0.75 g of BOC 
anhydride and 0.10 g of 5 % Pd/C. This solution was hydrogenated for 30 
minutes, at a pressure of 40 psi. After hydrogenation was completed, the solution 
was passed thought Celite to remove the Pd/C. The solvent was evaporated and 
the compound was purified by column chromatography to remove any excess 
BOC anhydride, eluting with EtOAc to afford 2.90 g of pure product, 15. 1H NMR 
(Varian 400 MHz; (DMSO−d6) δ: −0.07 (s, 9H); 0.77 − 0.83 (m, 2H), 1.16 − 1.22 
(m, 2H); 1.27 (s, 9H);  1.35 − 1.41 (m, 2H); 1.46 − 1.61 (m, 2H), 2.91 − 2.97 (dd, 
2H, J = 6.66 Hz, J = 13.0 Hz); 3.57 (s, 3H); 3.88 − 3.90 (t, 2H, J = 7.90 Hz); 4.03 
− 4.10 (dd, 1H, J = 7.45 Hz, J = 13.5 Hz); 4.72 − 4.76 (t, 1H, J = 8.46 Hz); 4.80 
− 4.83 (m, 2H); 4.84 − 4.90 ( t, 1H, J  = 8.30 Hz); 6.39 − 6.41 (d, 1H, J = 7.95 Hz); 
6.43 − 6.45 (d, 1H, J = 7.83 Hz); 6.55 − 6.57 (d, 1H, J = 7.49 Hz); 6.82 − 6.84 (d, 
1H, J = 8.27 Hz); 6.94 − 6.96 (m, 2H); 7.07 − 7.36 (m, 20H); 7.54 − 7.56 (d, 1H, J 
= 8.88 Hz). 13C NMR (Varian 400 MHz; (DMSO-d6) δ:  −1.50, 17.29, 22.41, 
28.29, 29.18, 31.61, 51.60, 52.51, 57.80, 57.99, 58.44, 59.94, 61.66, 77.36, 
126.52, 126.64, 126.80, 127.13, 127.24, 127.37, 127.48, 127.60, 127.68, 127.75, 
127.84, 128.35, 140.55, 140.57, 141.01, 141.42, 155.58, 155.85, 157.03, 157.26, 
173.56. MALDI−TOF−MS: m/z 781 [M−Boc], 782 [M+H−Boc], 881 [M+], 903 
[M+Na], 904 [M+H+Na], 919 [M+K].  Anal. Calc: C, 65.43; H, 7.32; N, 9.54; O, 
14.53; Si, 3.19. Found: C, 65.01; H, 7.23; N, 9.51; Si, 3.17. 
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Teoc−S,S−Boc−Lys−Trimer Acid 
2.50 g (2.83 mmol) of Teoc−S,S−Boc−Lys−Trimer, 15, was dissolved in 5 mL of 
MeOH. The resulting solution was chilled to − 10 °C and 2.27 mL of ice-cold 1.00 
M LiOH was carefully added dropwise with vigorous stirring. After addition of 
LiOH was completed, the reaction was warmed to 0 °C and was allowed to stir 
for 30 minutes. Next, 1.00 M of ice−cold HCl was added dropwise to neutralize 
the LiOH. After complete addition of HCl and white precipitate fell out of solution 
and the pH of solution was checked to ensure its acidic nature. The white solid 
was filtered to afford 2.03 g (96.9 %) of the carboxylic acid product, 16. 1H NMR 
(Varian 400 MHz; (DMSO−d6)δ: −0.06 (s, 9H); 0.75 − 0.82 (m, 2H), 1.14 − 1.21 
(m, 2H); 1.26 (s, 9H);  1.34 − 1.40 (m, 2H); 1.44 − 1.60 (m, 2H), 2.90 − 2.97 (dd, 
2H, J = 6.63 Hz, J = 13.1 Hz); 3.89 − 3 .91 (t, 2H, J = 7.88 Hz); 4.02 − 4.09 (dd, 
1H, J = 7.43 Hz, J = 13.2 Hz); 4.73 − 4.77 (t, 1H, J = 8.46 Hz); 4.81 − 4.84 (m, 
2H); 4.86 − 4.93 ( t, 1H, J  = 8.35 Hz); 6.40 − 6.42 (d, 1H, J = 7.93 Hz); 6.45 
− 6.47 (d, 1H, J = 7.81 Hz); 6.55 − 6.57 (d, 1H, J = 7.50 Hz); 6.83 − 6.85 (d, 1H, J 
= 8.28 Hz); 6.95 − 6.98 (m, 2H); 7.09 − 7.36 (m, 20H); 7.55 − 7.57 (d, 1H, J = 
8.84 Hz).  13C NMR (Varian 400 MHz; (DMSO−d6) δ:   −1.44, 17.22, 22.04, 
28.19, 29.18, 31.60, 51.59, 52.51, 57.79, 57.98, 58.34, 59.84, 77.32, 126.52, 
126.64, 126.80, 127.13, 127.24, 127.40, 127.43, 127.61, 127.67, 127.75, 127.84, 
128.35, 140.05, 140.47, 140.96, 141.45, 155.60, 155.75, 157.15, 157.30. MALDI-
TOF-MS: m/z 721 [M−Boc−CO2], 749 [M−Boc−H2O], 750 [M+H−Boc−H2O], 849 
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[M−H2O], 871 [M−H2O+Na], 872 [M+H−H2O+Na]. Anal. Calc: C, 65.10; H, 7.21; 
N, 9.69; Si, 3.24. Found: C, 64.97; H, 7.53; N, 9.77; Si, 3.26. 
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R, R−Cbz−Boc−Lys−Trimer 
In a 100 mL round bottom flask charged with 25 mL DMF was added 2.30 g (5.54 
mmol) of ε−Cbz−(S)−Lysine α−PNP Carbamate Methyl Ester, 2.80 g (5.23 mmol) 
of R,R-Mono-Boc dimer. A solution of TEA in 5 mL DMF was added dropwise 
into the previously mentioned flask. After addition was complete, the solution was 
warmed to 50 °C with stirring for a 24 hr period. After the period elapsed, DMF 
was removed via high vacuum rotary evaporation. The residue was suspended in 
EtOAc and passed through a short pad of Alumina, which traps the 
p−nitrophenoxide anion.  EtOAc was reduced to 10 mL and the mixture was 
chromatographed over silica eluting with a 55:45 mixture of EtOAc/hexanes. Rf = 
0.30 The organic portions were combined; the solvents removed affording 4.27 g 
(93.8 %) of the fully protected trimer. 1H NMR (Varian 400 MHz; (DMSO−d6) δ:  
1.15 − 1.21 (m, 2H); 1.26 (s, 9H); 1.30 − 1.36 (m, 2H); 1.46 − 1.61 (m, 2H); 2.95 
(dd, 1H; J = 6.73 Hz, J = 12. 8 Hz); 3.52 (s, 3H); 4.60 (dd, 1H, J = 7.77 Hz, J = 
13.5 Hz); 4.76 (t, 1H, J = 8.6 Hz); 4.82 − 4.84 (m, 2H); 4.90 (t, 1H, J = 8.4 Hz); 
5.01 (s, 2H); 6.46 − 6.48 (d, 1H, J = 7.51 Hz); 6.78 − 6.81 (d, 1H, J = 8.83 Hz); 
6.82 − 6.85 (d, 1H, J = 8.85 Hz); 6.92 − 6.95 (m, 4H); 7.10 − 7.37 (m, 25H). 13C 
NMR (Varian 400 MHz; (DMSO−d6) δ:   22.54, 28.34, 29.11, 31.74, 51.88 52.43, 
57.99, 58.00, 58.42, 59.55, 65.29, 77.83 126.62, 126.78, 127.29, 127.29, 127.53, 
127.47, 127.65, 127.79, 127.76, 128.45, 137.32, 140.48, 141.16, 141.52, 155.17, 
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156.14, 156.99, 157.26, 173.62. MALDI−TOF−MS: m/z 771 [M−Boc], 793 
[M+H−Boc], 871 [M+], 872 [M+H], 893 [M+Na],  894 [M+H+Na],  909 [M+K],  
910[M+H+K].   Anal. Calc: C, 68.95; H, 6.71; N, 9.65. Found: C, 68.89; H, 6.61; 
N, 9.58. 
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Teoc−R, R−Cbz−Lys−Trimer 
The previously synthesized R,R−Cbz−Lys−Trimer, 31, in the amount of 2.50 g 
(2.87 mmol) was submitted to deprotection conditions using 3 eq. of TFA in 10 
mL DCM for a 24 hr period. Afterwards, excess TFA and DCM were removed by 
rotary evaporation leaving behind a syrupy residue. This residue was dissolved 
10 mL of DCM and washed 5 times with saturated NaHCO3 solution. The organic 
layer was saved and dried over anhydrous NaSO4. The salts were filtered and 
DCM removed. Next, 10 mL of DMF were added along with 3 eq. of Teoc 
Carbonate, 47 and allowed to stir at room temperature for 24 hrs. The next day, 
DMF was removed via high vacuum rotary evaporation. The resulting residue 
was taken up in EtOAc and chromatographed over alumina, eluting with 50/50 
EtOAc/hexane. The solvents were removed affording 2.45 g of Teoc−R, 
R−Cbz−Lys−Trimer, 32, with a yield of 93.2 %. 1H NMR (Varian 400 MHz; 
(DMSO−d6)  δ: −0.07 (s, 9H); 0.79 − 0.85 (m, 2H); 1.12 − 1.20 (m, 2H); 1.28 
− 1.37 (m, 2H); 1.42 − 1.60 (m, 2H); 2.87 − 2.94 (q, 2H, J = 6.68 Hz, J = 13.0 Hz); 
3.60 (s, 3H); 3.88 − 3.92 (t, 2H, J = 5.45 Hz, J = 10.3 Hz); 4.05−4.12 (q, 1H, J = 
7.44 Hz, J = 13.5 Hz); 4.72 − 4.77 (t, 1H, J = 8.43 Hz); 4.79 − 4.83 (m, 2H); 4.85 - 
4.88 (t, 1H, J = 8.28 Hz); 4.97 (s, 2H); 6.39 − 6.41 (d, 1H, J = 7.97 Hz); 6.43 
− 6.47 (d, 1H, J = 7.76 Hz); 6.45 − 6.58 (d, 1H, J = 7.49 Hz); 6.77 − 6.81 (d, 1H, J 
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= 8.30 Hz); 6.87 − 6.96 (m, 2H); 7.20 − 7.36 (m, 25H); 7.53 − 7.58 (d, 1H, J = 
8.87 Hz). 13C NMR (Varian 400 MHz; (DMSO−d6) δ:    −1.40, 17.32, 22.32, 
28.33, 29.22, 31.61, 51.59, 52.32, 52.58, 57.81, 57.95, 58.40, 58.48, 61.62, 
77.45, 126.63, 126.67, 127.15, 127.24, 127.27, 127.40, 127.45, 127.61, 127.67, 
127.77, 127.90, 139.96, 140.53, 141.03, 141.44, 155.57, 157.15, 157.72, 159.25, 
173.59. MALDI−TOF−MS: m/z  915 [M+], 916 [M+H], 937 [M+Na], 938 [M+H+K]. 
Anal. Calc: C, 66.93; H, 6.83; N, 9.18; Si, 3.07. Found: C, 66.90; H, 6.73; N, 
9.16; Si, 3.00.  
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Teoc−R, R−Boc−Lys−Trimer 
In a small hydrogenation flask were added, 1.75 g (1.91 mmol) of the 
Teoc−R,R−Cbz-Lys-Trimer, 32 along with 10 mL of anhydrous MeOH, 0.50 g 
(2.28 mmol) of BOC anhydride and 0.10 g of 5 % Pd/C. This solution was 
hydrogenated for 30 minutes, at a pressure of 40 psi. After the reaction was 
completed, the solution was passed through Celite (filtering aid) to remove the 
Pd/C. The solvent was evaporated and the compound was purified by column 
chromatography to remove any excess BOC anhydride, eluting with EtOAc to 
afford quantitatively, 1.69 g of 33. 1H NMR (Varian 400 MHz; (DMSO−d6)  
δ:  −0.09 (s, 9H); 0.89 − 0.93 (m, 2H); 1.14 − 1.23 (m, 2H); 1.26 (s, 9H);  1.30 
− 1.37 (m, 2H); 1.43 − 1.62 (m, 2H), 2.85 − 2.97 (dd, 2H, J = 6.63 Hz, J = 12.8 
Hz); 3.60 (s, 3H); 3.92 − 3.94 (t, 2H, J = 7.92 Hz J = 10.43); 4.07 − 4.15 (dd, 1H, 
J = 7.48 Hz, J = 13.2 Hz); 4.76 − 4.80 (t, 1H, J = 8.42 Hz); 4.80 − 4.84 (m, 2H); 
4.89 − 4.95 ( t, 1H, J  = 8.33 Hz); 6.42 − 6.44 (d, 1H, J = 7.95 Hz); 6.47 − 6.51 (d, 
1H, J = 7.88 Hz); 6.57 − 6.59 (d, 1H, J = 7.47 Hz); 6.85 − 6.88 (d, 1H, J = 8.31 
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Hz); 6.90 − 6.97 (m, 2H); 7.10 − 7.34 (m, 20H); 7.57 − 7.60 (d, 1H, J = 8.89). 13C 
NMR (Varian 400 MHz; (DMSO−d6) δ: −1.47, 17.32, 22.45, 28.31, 29.23, 31.62, 
51.62, 52.53, 57.85, 58.00, 58.46, 59.99, 62.00, 77.40, 126.57, 126.69, 126.86, 
127.18, 127.30, 127.40, 127.48, 127.59, 127.66, 127.75, 127.86, 128.39, 140.72, 
140.62, 141.05, 141.47, 155.59, 155.87, 157.06, 157.30, 173.59. 
MALDI−TOF−MS: m/z 781 [M−Boc], 782 [M+H−Boc], 881[M+], 903 [M+Na], 904 
[M+H+Na], 919 [M+K]. Anal. Calc: C, 65.43; H, 7.32; N, 9.54; Si, 3.19. Found: 
C, 65.36; H, 7.33; N, 9.50; Si, 3.19. 
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Teoc−R, R−Boc−Lys−Trimer Acid 
1.25 g (1.41 mmol) of Teoc-R, R−Boc−Lys−Trimer, 33, was dissolved in 5 mL of 
MeOH. The resulting solution was chilled to −10 °C and 2.27 mL of ice−cold 1.00 
M LiOH was carefully added dropwise with vigorous stirring. After addition of 
LiOH was completed, the reaction was warmed to 0 °C and was allowed to stir 
for 30 minutes. Next, 1.00 M of ice−cold HCl was added dropwise to neutralize 
the LiOH. During the process of neutralization a white precipitate fell out of 
solution. After HCl addition was completed, the pH of solution was checked to 
ensure its acidic nature. The white solid was filtered to yield 1.00 g (96.9 %) of 
the carboxylic acid, 34. 1H NMR (Varian 400 MHz; (DMSO−d6)  δ:   −0.06 (s, 9H); 
0.85 − 0.92 (m, 2H), 1.14 − 1.21 (m, 2H); 1.27 (s, 9H);  1.34 − 1.40 (m, 2H); 1.44 
− 1.60 (m, 2H), 2.90 − 2.95 (dd, 2H, J = 6.63 Hz, J = 13.1 Hz); 3.89 − 3.91 (t, 2H, 
J = 7.88 Hz; J = 10.40 Hz); 4.02 − 4.09 (dd, 1H, J = 7.43 Hz, J = 13.2 Hz); 4.73 
− 4.77 (t, 1H, J = 8.46 Hz); 4.81 − 4.84 (m, 2H); 4.86 − 4.93 ( t, 1H, J  = 8.35 Hz); 
6.40 − 6.42 (d, 1H, J = 7.93 Hz); 6.45 − 6.47 (d, 1H, J = 7.81 Hz); 6.55 − 6.57 (d, 
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1H, J = 7.50 Hz); 6.83 − 6.85 (d, 1H, J = 8.28 Hz); 6.95 − 6.98 (m, 2H); 7.09 
− 7.36 (m, 20H); 7.55 − 7.57 (d, 1H, J = 8.84 Hz).  13C NMR (Varian 400 MHz; 
(DMSO−d6) δ:   −1.44, 17.22, 22.04, 28.19, 29.18, 31.60, 51.59, 52.51, 57.79, 
57.98, 58.34, 59.84, 77.32, 126.52, 126.64, 126.80, 127.13, 127.24, 127.40, 
127.43, 127.61, 127.67, 127.75, 127.84, 128.35, 140.05, 140.47, 140.96, 141.45, 
155.60, 155.75, 157.15, 157.30. MALDI−TOF−MS: m/z 721 [M−Boc−CO2], 749 
[M−Boc−H2O], 750 [M+H−Boc−H2O], 849 [M−H2O], 871 [M−H2O+Na], 872 
[M+H−H2O+Na]. Anal. Calc: C, 65.10; H, 7.21; N, 9.69; O, 14.76; Si, 3.24. 
Found: C, 64.99; H, 7.15; N, 9.65; Si, 3.20. 
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S, S−Boc−Ala−Trimer−Ester 
In a 50 mL round bottom flask charged with 15 mL DMF was added 2.00 g (7.5 
mmol) of alanine carbamate, 43 and 4.00 g (7.32 mmol) of S,S−Mono−BOC 
dimer. A solution of 0.80 mL TEA in 5 mL DMF was added dropwise into the flask 
containing the dimer and activated amino acid. After addition was complete, the 
solution was warmed to 50 °C with stirring for a 24 hr. period. The solvent, DMF 
was removed via high vacuum rotary evaporation. The residue was suspended in 
10 mL EtOAc and passed through a short pad of alumina, trapping the 
p−nitrophenoxide anion. The mixture, now devoid of the yellow p−nitrophenoxide 
anion was chromatographed over silica eluting with 80:20 mixture of 
EtOAc/hexane affording 3.83 (80.9 % yield) of 20.  1H NMR (Varian 400 MHz; 
(DMSO−d6) δ: 1.17 − 1.19 (d, 3H, J = 7.24 Hz); 1.23 (s, 9H); 3.60 (s, 3H); 4.09 
− 4.17(m, 1H); 4.73 − 4.76 (t, 1H, J = 8.03 Hz); 4.79 − 4.82 (m, 2H); 4.86 − 4.91 
(t, 1H, J = 8.10 Hz, J = 8.10 Hz); 6.38 − 6.40 (d, 1H, J = 6.90 Hz); 6.56 − 6.60 (d, 
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1H, J = 7.76 Hz); 6.81 − 6.83 (d, 1H, J = 8.1 Hz); 6.86 − 6.89 (d, 1H, J = 7.60 Hz); 
6.90 − 6.95 (d, 1H, J = 7.57 Hz); 7.09 − 7.25 (m, 20H). 13C NMR (Varian 400 
MHz; (DMSO−d6) δ:   17.1, 28.7, 50.4, 53.6, 56.9, 58.2, 59.4, 61.65, 77.4, 
126.24, 127.33, 127.38, 127.43, 127.59, 127.68, 141.02, 141.35, 155.22, 156.05, 
156.95, 173.97.  MALDI−TOF−MS: m/z 680 [M+], 681 [M+1], 703 [M+Na], 704 
[M+H+Na], 720 [M+K]. Anal. Calc: C, 68.90; H, 6.67; N, 10.30. Found: C, 68.09; 
H, 6.53; N, 10.20. 
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Teoc−S, S−Ala−Trimer Ester 
2.75 g (4.24 mmol) of compound 20 was submitted to deprotection conditions 
using 3.0 eq of TFA in 10.0 mL DCM for a 24 hour period. After the period 
elapsed, excess TFA and DCM were removed by rotary evaporation leaving 
behind a residue. The residue was dissolved in 10.0 mL DCM and washed 3 
times with saturated NaHCO3 solution. The organic layer was dried over 
anhydrous Na2SO4. The salts were filtered and solvent removed. Next, DMF was 
added along with 3 eq. of Teoc carbonate, 47. This solution was allowed to stir at 
room temperature for 24 hrs. The next day, DMF was removed via high vacuum 
rotary evaporation. The resulting residue was taken up in EtOAc and 
chromatographed over alumina, eluting with 40/60 EtOAc/hexane. The solvents 
were removed affording 2.80 g, 91.8 % of Teoc−S, S−Ala−Trimer, 21. 1H NMR 
(Varian 400 MHz; (DMSO−d6) δ:     −0.04 (s, 9H); 0.0782 − 0.823 (m, 2H); 1.18 
− 1.20 (d, 3H, J = 7.22 Hz); 3.55 (s, 3H); 3.87 − 3.92 (m, 2H); 4.09 − 4.17 (m, 
1H); 4.73 − 4.77 (dd, 1H, J = 8.59 Hz, J = 8.30 Hz); 4.79 − 4.83 (m, 2H); 4.85 
− 4.89 (dd, 1H, J = 8.14 Hz, J = 8.14 Hz); 6.34 − 6.38 (d, 1H, J = 7.53 Hz); 6.42 
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− 6.45 (d, 1H, J = 7.41 Hz); 6.57 − 6.59 (d, 1H, J = 7.97 Hz); 6.80 − 6.84 (d, 1H, J 
= 8.45 Hz); 7.08 − 7.20 (m, 20H); 7.55 − 7.58 (d, 1H, J = 8.98 Hz). 13C NMR 
(Varian 400 MHz; (DMSO−d6) δ:   −1.47, 17.24, 18.07, 48.20, 57.96, 58.77, 
59.96, 61.65, 79.17, 126.64, 127.13, 27.34, 127.49, 127.68, 127.78, 141.03, 
141.43, 155.83, 157.06, 157.14, 174.06. MALDI−TOF−MS: 680 [M+], 681 [M+1], 
703 M+Na], 704 [M+H+Na], 720 [M+K].  Anal. Calc: C, 66.36; H, 6.82; N, 9.67; 
Si, 3.88. Found: C, 66.26; H, 6.77; N, 9.63; Si, 3.86. 
HN
NH
Ph
Ph
O
N
H
Ph
PhNHHN
O
HO
O
CH3
O
O
SiMe3
22
 
Teoc−S,S−Ala−Trimer Acid 
2.00 g (2.77 mmol) of Teoc-S, S-Ala-Trimer, 21 was dissolved in 5 mL of MeOH. 
The resulting solution was chilled to −10 °C and 2.77 mL of ice−cold 1.00 M LiOH 
was carefully added dropwise with vigorous stirring. After addition of LiOH was 
completed, the reaction was warmed to 0 °C and was allowed to stir for 30 
minutes. Next, 1.00 M of ice-cold HCl was added dropwise to neutralize the 
LiOH. After complete addition of HCl and white precipitate fell out of solution and 
the pH of solution was checked to ensure its acidic nature. The white solid was 
filtered to afford 1.84 g (94.1 %) of 22. 1H NMR (Varian 400 MHz; (DMSO−d6) δ: 
−0.05 (s, 9H); 0.081 − 0.83 (m, 2H); 1.28 − 1.30 (d, 3H, J = 7.21 Hz); 3.88 − 3.92 
(m, 2H); 4.19 − 4.22 (m, 1H); 4.76 − 4.80 (dd, 1H, J = 8.61 Hz, J = 8.32 Hz); 4.83 
− 4.87 (m, 2H); 4.89 − 4.91 (dd, 1H, J = 8.16 Hz, J = 8.16 Hz); 6.37 − 6.41 (d, 1H, 
J = 7.54 Hz); 6.45 − 6.48 (d, 1H, J = 7.43 Hz); 6.59 − 6.61 (d, 1H, J = 8.00Hz); 
6.82 − 6.87 (d, 1H, J = 8.46 Hz); 7.10 − 7.21 (m, 20H); 7.57 − 7.60 (d, 1H, J = 
8.97 Hz). 13C NMR (Varian 400 MHz; (DMSO−d6) δ:  −1.44, 17.22, 18.10, 48.23, 
58.00, 58.77, 59.98, 79.15, 126.62, 127.16, 27.31, 127.52, 127.69, 128.01, 
 83
141.07, 141.48, 155.86, 157.11, 157.17. MALDI−TOF−MS: m/z 664[M−CO2], 
692[M−H2O], 693 [M+H−H2O], 714 [M+Na−H2O], 715 [M+H+Na−H2O].  Anal. 
Calc: C, 65.98; H, 6.67; N, 9.87; Si, 3.96. Found: C, 65.90; H, 6.59; N, 9.67; Si, 
3.89.  
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                                         R, R−Boc−Ala−Trimer−Ester 
In a 50 mL round bottom flask charged with 15 mL DMF was added 1.60 g (6.0 
mmol) of alanine carbamate, 43 and 3.21 g (5.88 mmol) of R, R−Mono−BOC 
dimer, 30. A solution of 0.80 mL TEA in 5 mL DMF was added dropwise into the 
flask containing the dimer and activated amino acid. After addition was complete, 
the solution was warmed to 50 °C with stirring for a 24 hr. period. The solvent, 
DMF was removed via high vacuum rotary evaporation. The residue was 
suspended in 10 mL EtOAc and passed through a short pad of alumina, trapping 
the p-nitrophenoxide anion. The mixture, now devoid of the yellow 
p−nitrophenoxide anion was chromatographed over silica eluting with 80:20 
mixture of EtOAc/hexanes affording 3.34 (83.7 % yield) of 38. 1H NMR (Varian 
400 MHz; (DMSO−d6) δ: 1.20 − 1.23 (d, 3H, J = 7.27 Hz); 1.26 (s, 9H); 3.58 (s, 
3H); 4.11−4.18 (m, 1H); 4.76 − 4.79 (t, 1H, J =8 .03); 4.82 − 4.84 (m, 2H); 4.88 
− 4.93 (t, 1H, J = 8.00 Hz, J = 8.00 Hz); 6.40 − 6.42 (d, 1H, J = 6.93 Hz); 6.62 − 
6.66 (d, 1H, J = 8.02 Hz); 6.85 − 6.87 (d, 1H, J = 8.3 Hz); 6.89 − 6.82 (d, 1H, J = 
7.63 Hz); 6.91 − 6.96 (d, 1H, J = 7.57 Hz); 7.11 − 7.23 (m, 20H). 13C NMR 
(Varian 400 MHz; (DMSO−d6) δ:  17.5, 29.0, 50.7, 53.6, 57.3, 58.9, 60.4, 62.3, 
78.4, 126.64, 127.13, 127.34, 127.49, 127.68, 127.78, 141.02, 141.36, 157.11, 
156.98, 174.0   MALDI−TOF−MS: m/z 680 [M+], 681 [M+1], 703 [M+Na], 704 
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[M+H+Na], 720 [M+K]. Anal. Calc: C, 68.90; H, 6.67; N, 10.30. Found: C, 68.77; 
H, 6.52; N, 10.11. 
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Teoc−R, R−Ala−Trimer Ester 
2.75 g (4.24 mmol) of compound 38 was submitted to deprotection conditions 
using 3.0 eq of TFA in 10.0 mL DCM for a 24 hour period. After the period 
elapsed, excess TFA and DCM were removed by rotary evaporation leaving 
behind a residue. The residue was dissolved in 10.0 mL DCM and washed 3 
times with saturated NaHCO3 solution. The organic layer was dried over 
anhydrous Na2SO4. The salts were filtered and solvent removed. Next, DMF was 
added along with 3 eq. of Teoc carbonate, 47. This solution was allowed to stir at 
room temperature for 24 hrs. The next day, DMF was removed via high vacuum 
rotary evaporation. The resulting residue was taken up in EtOAc and 
chromatographed over alumina, eluting with 40/60 EtOAc/hexane. The solvents 
were removed affording 2.82 g, 92.0 % of Teoc−R, R−Ala−Trimer, 39. 1H NMR 
(Varian 400 MHz; (DMSO−d6) δ:    −0.06 (s, 9H); 0.08 − 0.83 (m, 2H); 1.24 − 1.32 
(d, 3H, J = 7.27 Hz); 3.59 (s, 3H); 3.91 − 3.96 (m, 2H); 4.11 − 4.19 (m, 1H); 4.76 
− 4.80 (dd, 1H, J = 8.56 Hz, J = 8.27 Hz); 4.82 − 4.85 (m, 2H, J = 8.17 Hz, J = 
8.17 Hz); 4.89 − 4.92 (dd, 1H); 6.38 − 6.42 (d, 1H, J = 7.53 Hz); 6.45 − 6.48 (d, 
1H, J = 7.43 Hz); 6.60 − 6.62 (d, 1H, J = 7.98 Hz); 6.83 − 6.86 (d, 1H, J = 8.43 
Hz); 7.09 − 7.20 (m, 20H); 7.60 − 7.63 (d, 1H, J = 8.90 Hz). 13C NMR (Varian 400 
MHz; (DMSO-d6) δ:   −1.50, 17.28, 18.16, 48.27, 58.00, 59.02, 59.99, 61.72, 
79.37, 126.66, 127.11, 127.38, 127.52, 127.73, 127.83, 141.13, 141.48, 155.93, 
157.13, 157.34, 174.16.  Anal. Calc: C, 66.36; H, 6.82; N, 9.67; Si, 3.88. Found: 
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C, 66.16; H, 6.78; N, 9.60; Si, 3.80. MALDI−TOF−MS: m/z 680 [M+], 681 [M+1], 
703 [M+Na], 704 [M+H+Na], 720 [M+K]. Anal. Calc: C, 66.36; H, 6.82; N, 9.67; 
Si, 3.88. Found: C, 66.14; H, 6.65; N, 9.58; Si, 3.86. 
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Teoc−R, R−Ala−Trimer Acid 
2.00 g (2.77 mmol) of 39 was dissolved in 5 mL of MeOH. The resulting solution 
was chilled to −10 °C and 2.77 mL of ice−cold 1.00 M LiOH was carefully added 
dropwise with vigorous stirring. After addition of LiOH was completed, the 
reaction was warmed to 0 °C and was allowed to stir for 30 minutes. Next, 1.00 
M of ice−cold HCl was added dropwise to neutralize the LiOH. After complete 
addition of HCl and white precipitate fell out of solution and the pH of solution 
was checked to ensure its acidic nature. The white solid was filtered to afford 
1.88 g (95.7 %) of 41. 1H NMR (Varian 400 MHz; (DMSO−d6) δ: −0.05 (s, 9H); 
0.081−0.83 (m, 2H); 1.27 − 1.30 (d, 3H, J = 7.21 Hz); 3.88 − 3.92 (m, 2H); 4.19 − 
4.24 (m, 1H); 4.80 − 4.84 (dd, 1H, J = 8.65 Hz, J = 8.36 Hz); 4.83 − 4.87 (m, 2H); 
4.89 − 4.91 (dd, 1H, J = 8.16 Hz, J = 8.16 Hz); 6.37 − 6.41 (d, 1H, J = 7.54 Hz); 
6.46 − 6.50 (d, 1H, J = 7.45 Hz); 6.59 − 6.61 (d, 1H, J = 8.00 Hz); 6.82 − 6.87 (d, 
1H, J = 8.46 Hz); 7.10 − 7.21 (m, 20H); 7.57 − 7.60 (d, 1H, J = 8.93 Hz).  13C 
NMR (Varian 400 MHz; (DMSO−d6) δ:   −1.49, 17.24, 18.10, 48.23, 58.01, 58.77, 
59.98, 79.15, 126.67, 127.16, 127.31, 127.52, 127.69, 128.81, 141.07, 141.48, 
155.96, 157.14, 157.37. MALDI−TOF−MS: m/z 692 [M−H2O], 693 [M+H−H2O], 
714 [M+Na−H2O], 715 [M+H+Na−H2O].  Anal. Calc: C, 65.98; H, 6.67; N, 9.87; 
Si, 3.96. Found: C, 65.87; H, 6.59; N, 9.77; Si, 3.90. 
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3.8 Solid Phase Synthesis Protocols 
3.8.1 First Attempt 
 In a solid phase synthesizer reaction vessel was added 0.20 g (0.84 
mmol active sites) of Knorr resin, which was deprotected with treatment with 
three 30 minute washings with 20 % piperidine in DMF. Upon completion of the 
deprotection protocol, the resin beads were washed with MeOH for 10 minutes 
and then DCM for 2 minutes (for swelling). A small portion of beads were 
submitted to Kaiser test protocols to ensure that deprotection had taken place. 
Next, a previously prepared solution containing 0.50 g (0.576 mmol) of 
compound 16, 100 μL of Hunig’s base, 250 μL of DCM, 0.210 g (0.50 mmol) of 
Castro’s reagent and 0.08 g (0.60 mmol) of HOBt in 1 mL DMF. This solution 
was warmed to 50 °C and placed directly on the deprotected solid phase resin 
beads. The reaction vessel was carefully shaken for 24 hrs and after this period 
elapsed, a small sample of beads were removed, then washed with a 50/50 
mixture of DCM/DMF and submitted for Kaiser testing. The Kaiser tests on the 
beads were positive, indicating that coupling did not take place. The reaction was 
allowed to continue for 2 more days and a small portion of beads were removed 
and washed and submitted for Kaiser testing. Unfortunately, the test was 
positive, indicating that no reaction had taken place. The remaining solution was 
removed from the beads and the solution components checked by TLC to make 
sure that compound 16 had been completely converted to its active ester, which 
is needed for coupling.  
3.8.2 Second Attempt 
 In a solid phase synthesizer reaction vessel was added 0.20 g (0.84 
mmol active sites) of Knorr resin, which was deprotected with treatment with 
three 30 minute washings with 20 % piperidine in DMF. Upon completion of the 
deprotection protocol, the resin beads were washed with MeOH for 10 minutes 
and then DCM for 2 minutes (for swelling). A small portion of beads were 
submitted to Kaiser test protocols to ensure that deprotection had taken place. 
Next, a previously prepared solution containing 0.50 g (0.576 mmol) of 
compound 16, 100 μL of Hunig’s base, 250 μL of DCM, 0.210 g (0.50 mmol) of 
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Castro’s reagent and 0.08 g (0.60 mmol) of HOBt in 1 mL DMF. This solution 
was warmed to 50 °C and placed directly on the deprotected solid phase resin 
beads. The reaction vessel was carefully shaken for 1 week. After this period 
elapsed, a small sample of beads were removed, then washed with a 50/50 
mixture of DCM/DMF and submitted for Kaiser testing. The Kaiser tests on the 
beads were positive, indicating that coupling did not take place. No further 
attempts were taken with this material. 
3.8.3 Third Attempt 
 In a solid phase synthesizer reaction vessel was added 0.20 g (0.84 
mmol active sites) of Knorr resin, which was deprotected with treatment with 
three 30 minute washings with 20 % piperidine in DMF. Upon completion of the 
deprotection protocol, the resin beads were washed with MeOH for 10 minutes 
and then DCM for 2 minutes (for swelling). A small portion of beads were 
submitted to Kaiser test protocols to ensure that deprotection had taken place. 
Next, a previously prepared solution containing 0.50 g (0.576 mmol) of 
compound 34, 100 μL of Hunig’s base, 250 μL of DCM, 0.210 g (0.50 mmol) of 
Castro’s reagent and 0.08 g (0.60 mmol) of HOBt in 1 mL DMF. This solution 
was warmed to 50 °C and placed directly on the deprotected solid phase resin 
beads. The reaction vessel was carefully shaken for 3 days at room temperature. 
After this period elapsed, a small sample of beads were removed, then washed 
with a 50/50 mixture of DCM/DMF and submitted for Kaiser testing. The Kaiser 
tests on the beads were positive, indicating that coupling did not take place. No 
further attempts were taken with this material. 
3.8.4   Fourth Attempt 
In a solid phase synthesizer reaction vessel was added 0.15 g (0.84 mmol active 
sites) of Knorr resin, which was deprotected with treatment with three 30 minute 
washings with 20 % piperidine in DMF. Upon completion of the deprotection 
protocol, the resin beads were washed with MeOH for 10 minutes and then DCM 
for 2 minutes (for swelling). A small portion of beads were submitted to Kaiser 
test protocols to ensure that deprotection had taken place. Next, a previously 
prepared solution containing 0.268 g (0.377 mmol) of compound 22, 50 μL of 
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Hunig’s base, 200 μL of DCM, 0.157 g (0.378 mmol) of Castro’s reagent and 
0.051 g (0.377 mmol) of HOBt in 0.75 mL of DMF. This solution was warmed to 
50 °C and placed directly on the deprotected solid phase resin beads. The 
reaction vessel was carefully shaken for 2 days at room temperature. After this 
period elapsed, a small sample of beads were removed, then washed with a 
50/50 mixture of DCM/DMF and submitted for Kaiser testing. The Kaiser tests on 
the beads were positive, indicating that coupling did not take place. No further 
attempts were taken with this material. 
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                                                         Chapter 4 
Conclusion 
The work presented in this dissertation was designed to elucidate the 
parameters necessary to create a novel helical-like peptidomimetic motif, which 
was based on the naturally occurring α−helical antibiotic peptide, Magainin. Also, 
presented in this work were the solution phase syntheses of small oligoureas 
(trimers) and various attempts to connect these “trimers” together using solid 
phase synthesis. This project surfaced from earlier studies which utilized short 
oligoureas sequences which contained the C2 symmetric trans−1, 
2−diaminocyclohexane. The results from those earlier studies suggested 
oligoureas derived from C2 symmetric diamines would lead to a helical−like motif.  
The first step towards our peptidomimetic was to utilize molecular 
modeling to predict which oligourea conformations would be best, in terms of 
helicity and the periodic disposition of the basic side chains. Unfortunately, 
because of the way modeling programs find energy minima, the carbonyl groups 
in the S, S and R, R conformers were pointed in the same direction, helping the 
conformational search to avoid producing a local mimina. Next, Monte Carlo 
searches were used to explore the molecular dynamics on the potential 
molecules.19 These searches were initiated from helical−like conformations, 
consisting of 12 monomer units, with the carbonyl groups pointed in the same 
direction. The best results from this conformational search, which used the force 
field, Amber (CH3Cl continuum dielectric field) produced, within a window of 25 
kJ/mol (1000 max iterations for each cycle), 48 possible lowest energy 
structures. These results gave indication of an energetic preference for a right-
handed helical-like motif. This right handed motif was composed mainly of C2 
symmetric diamine molecules that possess S, S stereochemistry. As shown in 
(Figures 1.12 a−d), the right handed helical-like motif is more ordered with the 
carbonyls pointing generally in the same direction. This allows for ease of 
hydrogen bonding and cooperativity between different subunits, eventually 
leading to stabilization of the structure and positioning of the amino acid side 
chain preferentially on one side. However, the left handed helical-like motif 
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(Figures 1.12 e−f) is not ordered and does not have the carbonyl groups pointing 
in one direction and it does not have the lysine side chains positioned 
preferentially on one side of the motif. 
Using the results of the conformational search, a synthetic plan was 
implemented to make the small oligoureas. Unfortunately, two major problems 
needed to be overcome. One problem was the need for large quantities of the 
parent compound 1,2-diphenyl−1,2−diamine (DPDA), due to the many protecting 
group manipulations required in the synthesis. The second problem was wasting 
half of the diamine material for mono-protection. Luckily, in both cases, there 
existed, in the literature, procedures to produce mass quantities of the parent 
diamine (both enantiomers), as well as a method to mono-protect the diamine. 
Next, two orthogonally protected C2 symmetric diamines were successfully 
coupled via a urea linkage (R,R and S,S diamines were used), leading to an 
orthogonally protected molecule (dimer). These dimers were deprotected on one 
end and eventually coupled to either a protected and activated lysine or a 
protected and activated alanine, creating a short sequence of oligoureas 
(trimers), containing an amino acid residue. The last step was connection of the 
various trimers together by an amide bond linkage. Solution phase syntheses of 
these compounds are quite problematic due to purification and overall yield of the 
synthesis. However, a solid−phase synthetic approach has worked quite well, for 
peptides and other oligomers. Therefore, attempts to connect the oligourea 
trimers were attempted using a solid−phase synthesis approach to generate a 
functional magainin mimic. Several attempts were tried; unfortunately none of the 
solid phase couplings worked. One of the possible reasons why coupling did not 
occur could have been caused by the nature of the solid phase resin itself. It is 
known that certain solid phase resins are incompatible with different types of 
molecules, as well as synthetic procedures due to the size, solubility and other 
resin characteristics. Another possible reason why coupling did not occur could 
have been related to the size of the trimers themselves. Steric interactions 
between the trimer and the resin could prevent the coupling of the trimer and the 
functionalized resin.  
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                                                         Appendix 
 
A. 1  Crystal coordinates for structure 6b. 
 
            Atomic coordinates ( x 10^4) and equivalent isotropic 
            displacement parameters (A^2 x 10^3) for 6b. 
            U(eq) is defined as one third of the trace of the orthogonalized 
            Uij tensor. 
 
________________________________________________________ 
                                   x                      y                    z                     U(eq) 
________________________________________________________ 
 
N(1)          11251(3)           234(3)            1193(1)             45(1) 
N(2)          11421(3)           703(3)            441(1)               42(1) 
C(1)          12720(4)           98(4)              1059(1)             43(1) 
C(2)          12942(4)           592(4)            540(1)               43(1) 
C(3)          10637(4)           531(3)            824(1)               36(1) 
C(4)          9046(4)             618(3)            838(1)               42(1) 
F(1)           7720(3)           -858(3)            744(1)               102(1) 
F(2)           8768(2)            1083(2)          1238(1)             56(1) 
F(3)           9037(3)            1688(3)          539(1)               73(1) 
C(5)          12515(4)         -1603(4)          1151(1)             37(1) 
C(6)          13906(4)         -1770(4)          1250(1)             49(1) 
C(7)          13732(5)         -3337(5)          1329(1)             61(1) 
C(8)          12161(5)         -4751(4)          1308(1)             62(1) 
C(9)          10773(5)         -4610(4)          1202(1)             60(1) 
C(10)        10956(4)         -3048(4)          1128(1)             49(1) 
C(11)        14539(3)          2225(4)           434(1)              40(1) 
C(12)        15059(4)          3612(5)           706(1)              62(1) 
C(13)        16494(5)          5101(5)           610(1)              77(1) 
C(14)        17460(4)          5245(6)           239(1)              77(1) 
C(15)        16955(5)          3882(7)          -34(1)                85(2) 
C(16)        15498(5)          2333(6)           63(1)                69(1) 
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A. 2  Mono−TFA Diamine, 6, 1H NMR 
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A. 3  Mono−TFA Diamine, 6, 13C NMR 
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A. 4  Orthogonally Protected S,S−TFA/BOC Dimer, 11, 1H NMR 
 
 
 
 
HN
NH
Ph
Ph
O
O
O
N
H
NH
Ph
PhF3C
O
11
 95
A. 5  Orthogonally Protected S,S−TFA/BOC Dimer, 11, 13C NMR 
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A. 6 ε−Cbz−(S)−Lysine−α−PNP Carbamate Methyl Ester, 41,  1H NMR 
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A. 7 ε−Cbz−(S)−Lysine−α−PNP Carbamate Methyl Ester, 41,  13C NMR 
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A. 8  Boc−S,S−(Z)−Lys−Trimer, 13,  1H NMR 
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A. 9  Boc−S,S−(Z)−Lys−Trimer, 13,  13C NMR 
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A. 10  Boc−S,S−(Z)−Lys−Trimer, 13,  MALDI−TOF−MS 
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A. 11  Teoc−S,S−(Z)−Lys−Trimer, 14,  1H NMR 
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A. 12  Teoc−S,S−(Z)−Lys−Trimer, 14,  13C NMR 
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A. 13 Teoc−S,S−(Z)−Lys−Trimer, 14,  MALDI−TOF−MS 
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A. 14   Teoc−S,S−Boc−Lys−Trimer Acid, 16, MALDI−TOF−MS 
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A. 15 S,S− Teoc−Ala−Trimer, 21,  1H NMR 
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A. 16 S, S−Teoc−Ala−Trimer, 21, 13C NMR 
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A. 17 S,S−Teoc−Ala−Trimer, 21, MALDI−TOF−MS 
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A. 18 S,S−Teoc−Ala−Trimer Acid, 22, MALDI−TOF−MS 
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A. 19 Picture of Protected Knorr Resin Beads 
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A. 20 Picture of deprotected Knorr Resin Beads after Kaiser Test 
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